CA2511509C - Benzoazolylpiperazine derivatives having vr1 antagonist activity - Google Patents

Benzoazolylpiperazine derivatives having vr1 antagonist activity Download PDF

Info

Publication number
CA2511509C
CA2511509C CA2511509A CA2511509A CA2511509C CA 2511509 C CA2511509 C CA 2511509C CA 2511509 A CA2511509 A CA 2511509A CA 2511509 A CA2511509 A CA 2511509A CA 2511509 C CA2511509 C CA 2511509C
Authority
CA
Canada
Prior art keywords
another embodiment
halo
attached
group
carbon atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2511509A
Other languages
French (fr)
Other versions
CA2511509A1 (en
Inventor
Qun Sun
Laykea Tafesse
Sam Victory
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32686087&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2511509(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of CA2511509A1 publication Critical patent/CA2511509A1/en
Application granted granted Critical
Publication of CA2511509C publication Critical patent/CA2511509C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A compound of formula (I) wherein Ar1, A, R3, x, and m are as disclosed herein and Ar2 is a benzothiazolyl, benzooxazolyl, or benzoimidazolyl group or a pharmaceutically acceptable salt thereof (a ~Benzoazolylpiperazine Compound~), compositions comprising a Benzoazolylpiperazine Compound, and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson~s disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, retricted brain function, Huntington~s chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of Benzoazolylpiperazine Compound are disclosed.

Description

DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.

NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.

THIS IS VOLUME OF

NOTE: For additional volumes please contact the Canadian Patent Office.

1. FIELD OF THE INVENTION
The present invention relates to Benzoazolylpiperazine Compounds, compositions comprising a Benzoazolylpiperazine Compound and methods for treating or preventing pain; urinary incontinence (Ui), an ulcer, inflammatory-bowel disease (IBD), irritable bowel syndrome (IBS), an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis (ALS), dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression, comprising administering to an animal in need thereof an effective amount of a Benzoazolylpiperazine Compound.
2. BACKGROUND OF THE INVENTION
Pain is the most common symptom for which patients seek medical advice and treatment. Pain can be acute or chronic. While acute pain is usually self-limited, chronic pain persists for 3 months or longer and can lead to significant changes in a patient's personality, lifestyle, functional ability and overall quality of life (K.M.
Foley, Pain, in Cecil Textbook of Medicine 100-107 (J.C. Bennett and F. Plum eds., 20th ed. 1996)).

Pain has been traditionally managed by administering non-opioid analgesics, such as acetylsalicylic acid, choline magnesium trisalicylate, acetaminophen, ibuprofen, fenoprofen, diflusinal, and naproxen; or opioid analgesics, including morphine, hydromorphone, methadone, levorphanol, fentanyl, oxycodone, and oxymorphone.
Id.

UI is uncontrollable urination, generally caused by bladder-detrusor-muscle instability. UI affects people of all ages and levels of physical health, both in health care settings and in the community at large. At present, UI afflicts 15-30% of elderly people living at home, one-third of those living in acute-care settings, and at least one-half of those living in long-term care institutions (R.M. Resnick, Lancet 346:94 (1995)).
Persons having UI are predisposed to also having urinary-tract infections, pressure ulcers, perineal rashes and urosepsis. Psychosocially, UI is associated with embarrassment, social stigmatization, depression and a risk of institutionalization (Herzo et al., Annu. Rev.
Gerontol. Geriatr. 9:74 (1989)). Economically, the costs of UI are great; in the United States alone, health-care costs associated with UI are over $15 billion per annum.

Physiologic bladder contraction results in large part from acetylcholine-induced stimulation of post-ganglionic muscarinic-receptor sites on bladder smooth muscle.
Treatments for UI include the administration of drugs having bladder-relaxant properties, which help to control bladder-detrusor-muscle overactivity. For example, anticholinergics such as propantheline bromide and glycopyrrolate, and combinations of smooth-muscle relaxants such as a combination of racemic oxybutynin and dicyclomine or an anticholinergic, have been used to treat UI (See, e.g., A.J. Wein, Urol. Clin. N. Am. 22:557-577 (1995); Levin et al., J. Urol. 128:396-398 (1982); Cooke et al., S. Afr. Med. J. 63:3 (1983); R.K. Mirakhur et al., Anaesthesia 38:1195-1204 (1983)). These drugs are not effective, however, in all patients having uninhibited bladder contractions. Administration of anticholinergic medications represent the mainstay of this type of treatment.

None of the existing commercial drug treatments for UI, however, has achieved complete success in all classes of UI patients, nor has treatment occurred without significant adverse side effects. For example, drowsiness, dry mouth, constipation, blurred vision, headaches, tachycardia, and cardiac arrhythmia, which are related to the anticholinergic activity of traditional anti-UI drugs, can occur frequently and adversely affect patient compliance. Yet despite the prevalence of unwanted anticholinergic effects in many patients, anticholinergic drugs are currently prescribed for patients having UI. The Merck Manual of Medical Information 631-634 (R. Berkow ed., 1997).

Ulcers are sores occurring where the lining of the digestive tract has been eroded by stomach acids or digestive juices. The sores are typically well-defined round or oval lesions primarily occurring in the stomach and duodenum. About 1 in 10 people develop an ulcer. Ulcers develop as a result of an imbalance between acid-secretory factors, also known as "aggressive factors," such as stomach acid, pepsin, and Helicobacter pylori infection, and local mucosal-protective factors, such as secretion of bicarbonate, mucus, and prostaglandins.

Treatment of ulcers typically involves reducing or inhibiting the aggressive factors. For example, antacids such as aluminum hydroxide, magnesium hydroxide, sodium bicarbonate, and calcium bicarbonate can be used to neutralize stomach acids.
Antacids, however, can cause alkalosis, leading to nausea, headache, and weakness.
Antacids can also interfere with the absorption of other drugs into the blood stream and cause diarrhea.

H2 antagonists, such as cimetidine, ranitidine, famotidine, and nizatidine, are also used to treat ulcers. H2 antagonists promote ulcer healing by reducing gastric acid and digestive-enzyme secretion elicited by histamine and other H2 agonists in the stomach and duodenum. H2 antagonists, however, can cause breast enlargement and impotence in men, mental changes (especially in the elderly), headache, dizziness, nausea, myalgia, diarrhea, rash, and fever.

H}, K- - ATPase inhibitors such as omeprazole and lansoprazole are also used to treat ulcers. H+, K+ - ATPase inhibitors inhibit the production of enzymes used by the stomach to secrete acid. Side effects associated with H, KK - ATPase inhibitors include nausea, diarrhea, abdominal colic, headache, dizziness, somnolence, skin rashes, and transient elevations of plasma activities of aminotransferases.

Sucraflate is also used to treat ulcers. Sucraflate adheres to epithelial cells and is believed to form a protective coating at the base of an ulcer to promote healing. Sucraflate, however, can cause constipation, dry mouth, and interfere with the absorption of other drugs.
Antibiotics are used when Helicobacterpylori is the underlying cause of the ulcer. Often antibiotic therapy is coupled with the administration of bismuth compounds such as bismuth subsalicylate and colloidal bismuth citrate. The bismuth compounds are believed to enhance secretion of mucous and HC03 , inhibit pepsin activity, and act as an antibacterial against H. pylori. Ingestion of bismuth compounds, however, can lead to elevated plasma concentrations of Bi+3 and can interfere with the absorption of other drugs.

Prostaglandin analogues, such as misoprostal, inhibit secretion of acid and stimulate the secretion of mucous and bicarbonate and are also used to treat ulcers, especially ulcers in patients who require nonsteroidal anti-inflammatory drugs. Effective oral doses of prostaglandin analogues, however, can cause diarrhea and abdominal cramping.
In addition, some prostaglandin analogues are abortifacients.
Carbenoxolone, a mineral corticoid, can also be used to treat ulcers.
Carbenoxolone appears to alter the composition and quantity of mucous, thereby enhancing the mucosal barrier. Carbenoxolone, however, can lead to Na+ and fluid retention, hypertension, hypokalemia, and impaired glucose tolerance.

Muscarinic cholinergic antagonists such as pirenzapine and telenzapine can also be used to reduce acid secretion and treat ulcers. Side effects of muscarinic cholinergic antagonists include dry mouth, blurred vision, and constipation. The Merck Manual of Medical Information 496-500 (R. Berkow ed., 1997) and Goodman and Gilman's The Pharmacological Basis of Therapeutics 901-915 (J. Hardman and L. Limbird eds., 9th ed.
1996).

IBD is a chronic disorder in which the bowel becomes inflamed, often causing recurring abdominal cramps and diarrhea. The two types of IBD are Crohn's disease and ulcerative colitis.

Crohn's disease, which can include regional enteritis, granulomatous ileitis, and ileocolitis, is a chronic inflammation of the intestinal wall. Crohn's disease occurs equally in both sexes and is more common in Jews of eastern-European ancestry.
Most cases of Crohn's disease begin before age 30 and the majority start between the ages of 14 and 24.

The disease typically affects the full thickness of the intestinal wall.
Generally the disease affects the lowest portion of the small intestine (ileum) and the large intestine, but can occur in any part of the digestive tract.

Early symptoms of Crohn's disease are chronic diarrhea, crampy abdominal pain, fever, loss of appetite, and weight loss. Complications associated with Crohn's disease include the development of intestinal obstructions, abnormal connecting channels (fistulas), and abscesses. The risk of cancer of the large intestine is increased in people who have Crohn's disease. Often Crohn's disease is associated with other disorders such as gallstones, inadequate absorption of nutrients, amyloidosis, arthritis, episcleritis, aphthous stomatitis, erythema nodosum, pyoderma gangrenosum, ankylosing spondylitis, sacroilitis, uveitis, and primary sclerosing cholangitis. There is no known cure for Crohn's disease.

Cramps and diarrhea, side effects associated with Crohn's disease, can be relieved by anticholinergic drugs, diphenoxylate, loperamide, deodorized opium tincture, or codeine. Generally, the drug is taken orally before a meal.
Broad-spectrum antibiotics are often administered to treat the symptoms of Crohn's disease. The antibiotic metronidazole is often administered when the disease affects the large intestine or causes abscesses and fistulas around the anus. Long-term use of metronidazole, however, can damage nerves, resulting in pins-and-needles sensations in the arms and legs. Sulfasalazine and chemically related drugs can suppress mild inflammation, especially in the large intestine. These drugs, however, are less effective in sudden, severe flare-ups. Corticosteroids, such as prednisone, reduce fever and diarrhea and relieve abdominal pain and tenderness. Long-term corticosteroid therapy, however, invariably results in serious side effects such as high blood-sugar levels, increased risk of infection, osteoporosis, water retention, and fragility of the skin. Drugs such as azathioprine and mercaptourine can compromise the immune system and are often effective for Crohn's disease in patients that do not respond to other drugs. These drugs, however, usually need 3 to 6 months before they produce benefits and can cause serious side effects such as allergy, pancreatitis, and low white-blood-cell count.
When Crohn's disease causes the intestine to be obstructed or when abscesses or fistulas do not heal, surgery can be necessary to remove diseased sections of the intestine.
Surgery, however, does not cure the disease, and inflammation tends to recur where the intestine is rejoined. In almost half of the cases a second operation is needed. The Merck Manual of Medical Information 528-530 (R. Berkow ed., 1997).
Ulcerative colitis is a chronic disease in which the large intestine becomes inflamed and ulcerated, leading to episodes of bloody diarrhea, abdominal cramps, and fever.
Ulcerative colitis usually begins between ages 15 and 30; however, a small group of people have their first attack between ages 50 and 70. Unlike Crohn's disease, ulcerative colitis never affects the small intestine and does not affect the full thickness of the intestine. The disease usually begins in the rectum and the sigmoid colon and eventually spreads partially or completely through out the large intestine. The cause of ulcerative colitis is unknown.

Treatment of ulcerative colitis is directed to controlling inflammation, reducing symptoms, and replacing lost fluids and nutrients. Anticholinergic drugs and low doses of diphenoxylate or loperamide are administered for treating mild diarrhea. For more intense diarrhea higher doses of diphenoxylate or loperamide, or deodorized opium tincture or codeine are administered. Sulfasalazine, olsalazie, prednisone, or mesalamine can be used to reduce inflammation. Azathioprine and mercaptopurine have been used to maintain remissions in ulcerative-colitis patients who would otherwise need long-term corticosteroid treatment. In severe cases of ulcerative colitis the patient is hospitalized and given corticosteroids intravenously. People with severe rectal bleeding can require transfusions and intravenous fluids. If toxic colitis develops and treatments fail, surgery to remove the large intestine can be necessary. Non-emergency surgery can be performed if cancer is diagnosed, precancerous legions are detected, or unremitting chronic disease would otherwise make the person an invalid or dependent on high doses of corticosteroids. Complete removal of the large intestine and rectum permanently cures ulcerative colitis. The Merck Manual of Medical Information 530-532 (R. Berkow ed., 1997) and Goodman and Gilman's The Pharmacological Basis of Therapeutics Q. Hardman and L. Limbird eds., 9th ed.
1996).

IBS is a disorder of motility of the entire gastrointestinal tract, causing abdominal pain, constipation, and/or diarrhea. IBS affects three-times more women than men. In IBS stimuli such as stress, diet, drugs, hormones, or irritants can cause the gastrointestinal tract to contract abnormally. During an episode of IBS
contractions of the gastrointestinal tract become stronger and more frequent, resulting in the rapid transit of food and feces through the small intestine, often leading to diarrhea. Cramps result from the strong contractions of the large intestine and increased sensitivity of pain receptors in the large intestine.

There are two major types of IBS. The first type, spastic-colon type, is commonly triggered by eating, and usually produces periodic constipation and diarrhea with pain. Mucous often appears in the stool. The pain can come in bouts of continuous dull aching pain or cramps, usually in the lower abdomen. The person suffering from spastic-colon type IBS can also experience bloating, gas, nausea, headache, fatigue, depression, anxiety, and difficulty concentrating. The second type of IBS usually produces painless diarrhea or constipation. The diarrhea can begin suddenly and with extreme urgency. Often the diarrhea occurs soon after a meal and can sometimes occur immediately upon awakening.
Treatment of IBS typically involves modification of an IBS-patient's diet.
Often it is recommended that an IBS patient avoid beans, cabbage, sorbitol, and fructose. A
low-fat, high-fiber diet can also help some IBS patients. Regular physical activity can also help keep the gastrointestinal tract functioning properly. Drugs such as propantheline that slow the function of the gastrointestinal tract are generally not effective for treating IBS.
Antidiarrheal drugs, such as diphenoxylate and loperamide, help with diarrhea.
The Merck Manual of Medical Information 525-526 (R. Berkow ed., 1997).

Many drugs can cause physical and/or psychological addiction. Those most well known types of these drugs include opiates, such as heroin, opium, and morphine;

sympathomimetics, including cocaine and amphetamines; sedative-hypnotics, including alcohol, benzodiazepines and barbiturates; and nicotine, which has effects similar to opioids and sympathomimetics. Drug addiction is characterized by a craving or compulsion for taking the drug and an inability to limit its intake. Additionally, drug dependence is associated with drug tolerance, the loss of effect of the drug following repeated administration, and withdrawal, the appearance of physical and behavioral symptoms when the drug is not consumed. Sensitization occurs if repeated administration of a drug leads to an increased response to each dose. Tolerance, sensitization, and withdrawal are phenomena evidencing a change in the central nervous system resulting from continued use of the drug.
This change can motivate the addicted individual to continue consuming the drug despite serious social, legal, physical and/or professional consequences. (See, e.g., U.S. Patent No.
6,109,269 to Rise et al.).

Certain pharmaceutical agents have been administered for treating addiction.
U.S. Patent No. 5,556,838 to Mayer et al. discloses the use of nontoxic NMDA-blocking agents co-administered with an addictive substance to prevent the development of tolerance or withdrawal symptoms. U.S. Patent No. 5,574,052 to Rose et al. discloses co-administration of an addictive substance with an antagonist to partially block the pharmacological effects of the substance. U.S. Patent No. 5,075,341 to Mendelson et al.
discloses the use of a mixed opiate agonist/antagonist to treat cocaine and opiate addiction.
U.S. Patent No. 5,232,934 to Downs discloses administration of 3-phenoxypyridine to treat addiction. U.S. Patents No. 5,039,680 and 5,198,459 to Irnperato et al.
disclose using a serotonin antagonist to treat chemical addiction. U.S. Patent No. 5,556,837 to Nestler et. al.
discloses infusing BDNF or NT-4 growth factors to inhibit or reverse neurological adaptive changes that correlate with behavioral changes in an addicted individual. U.S.
Patent. No.
5,762,925 to Sagan discloses implanting encapsulated adrenal medullary cells into an animal's central nervous system to inhibit the development of opioid intolerance. U.S. Patent No. 6,204,284 to Beer et al. discloses racemic ( )-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane for use in the prevention or relief of a withdrawal syndrome resulting from addiction to drugs and for the treatment of chemical dependencies.
Parkinson's disease is a clinical syndrome comprising bradykinesia (slowness and poverty of movement), muscular rigidity, resting tremor (which usually abates during voluntary movement), and an impairment of postural balance leading to disturbance of gait and falling. The features of Parkinson's disease are a loss of pigmented, dopaminergic neurons of the substantia nigra pars compacta and the appearance of intracellular inclusions known as Lewy bodies (Goodman and Gillman's The Pharmaceutical Basis of Therapeutics 506 (9t'' ed. 1996)). Without treatment, Parkinson's disease progresses to a rigid akinetic state in which patients are incapable of caring for themselves. Death frequently results from complications of immobility, including aspiration pneumonia or pulmonary embolism. Drugs commonly used for the treatment of Parkinson's disease include carbidopa/levodopa, pergolide, bromocriptine, selegiline, amantadine, and trihexyphenidyl hydrochloride. There remains, however, a need for drugs useful for the treatment of Parkinson's disease and having an improved therapeutic profile.
Anxiety is a fear, apprehension, or dread of impending danger often accompanied by restlessness, tension, tachycardia, and dyspnea. Other symptoms commonly associated with anxiety include depression, especially accompanied with dysthymic disorder (chronic "neurotic" depression); panic disorder; agoraphobia and other specific phobias;
eating disorders; and many personality disorders. Often anxiety is unattached to a clearly identified treatable primary illness. If a primary illness is found, however, it can be desirable to deal with the anxiety at the same time as the primary illness.

Currently, benzodiazepines are the most commonly used anti-anxiety agents for generalized anxiety disorder. Benzodiazepines, however, carry the risk of producing impairment of cognition and skilled motor functions, particularly in the elderly, which can result in confusion, delerium, and falls with fractures. Sedatives are also commonly prescribed for treating anxiety. The azapirones, such as buspirone, are also used to treat moderate anxiety. The azapirones, however, are less useful for treating severe anxiety accompanied with panic attacks.
Epilepsy is a disorder characterized by the tendency to have recurring seizures.
The etiology commonly consists of lesions in some part of the cortex, such as a tumor;
developmental malformation; or damage due to trauma or stroke. In some cases the etiology is genetic. An epileptic seizure can be triggered by repetitive sounds, flashing lights, video games, or touching certain parts of the body. Epilepsy is typically treated with anti-seizure drugs. In epilepsy cases, where anti-seizure drugs are ineffective, and the defect in the brain is isolated to a small area of the brain, surgical removal of that part of the brain can be helpful in alleviating the seizures. In patients who have several sources for the seizures or who have seizures that spread quickly to all parts of the brain, surgical removal of the nerve fibers that connect the two sides of the brain can be helpful.

Examples of drugs for treating a seizure and epilepsy include carbamazepine, ethosuximide, gabapentin, lamotrignine, phenobarbital, phenytoin, primidone, valproic acid, trimethadione, bemzodiaepines, y-vinyl GABA, acetazolamide, and felbamate.
Anti-seizure drugs, however, can have side effects such as drowsiness; hyperactivity;
hallucinations;
inability to concentrate; central and peripheral nervous system toxicity, such as nystagmus, ataxia, diplopia, and vertigo; gingival hyperplasia; gastrointestinal disturbances such as nausea, vomiting, epigastric pain, and anorexia; endocrine effects such as inhibition of antidiuretic hormone, hyperglycemia, glycosuria, osteomalacia; and hypersensitivity such as scarlatiniform rash, morbilliform rash, Stevens-Johnson syndrome, systemic lupus erythematosus, and hepatic necrosis; and hematological reactions such as red-cell aplasia, agranulocytosis, thrombocytopenia, aplastic anemia, and megaloblastic anemia.
The Merck Manual of Medical Information 345-350 (R. Berkow ed., 1997).
A seizure is the result of abnormal electrical discharge in the brain. The discharge can involve a small area of the brain and lead to the person only noticing an odd taste or smell or it can involve a large area of the brain and lead to convulsions, i.e., a seizure that causes jerking and spasms of the muscles throughout the body. Convulsions can also result in brief attacks of altered consciousness and loss of consciousness, muscle control, or bladder control. A seizures is often preceded by auras, i.e., unusual sensations of smell, taste, or vision or an intense feeling that a seizure is about to begin. A seizure typically lasts for about 2 to 5 minutes. When the seizure ends the person can have headache, sore muscles, unusual sensations, confusion, and profound fatigue (postictal state). Usually the person cannot remember what happened during the seizure.

A stroke or cerebrovascular accident, is the death of brain tissue (cerebral infarction) resulting from the lack of blood flow and insufficient oxygen to the brain. A
stroke can be either ischemic or hemorrhagic. In an ischemic stroke, blood supply to the brain is cut off because of athersclerosis or a blood clot that has blocked a blood vessel. In a hemorrhagic stroke, a blood vessel bursts preventing normal blood flow and allowing blood to leak into an area of the brain and destroying it. Most strokes develop rapidly and cause brain damage within minutes. In some cases, however, strokes can continue to worsen for several hours or days. Symptoms of strokes vary depending on what part of the brain is effected. Symptoms include loss or abnormal sensations in an arm or leg or one side of the body, weakness or paralysis of an arm or leg or one side of the body, partial loss of vison or hearing, double vision, dizziness, slurred speech, difficulty in thinking of the appropriate word or saying it, inability to recognize parts of the body, unusual movements, loss of bladder control, imbalance, and falling, and fainting. The symptoms can be permanent and can be associated with coma or stupor. Strokes can cause edema or swelling of the brain which can further damage brain tissue. For persons suffering from a stroke, intensive rehabilitation can help overcome the disability caused by impairment of brain tissue.
Rehabilitation trains other parts of the brain to assume the tasks previously performed by the damaged part.

Examples of drugs for treating strokes include anticoagulants such as heparin, drugs that break up clots such as streptokinase or tissue plasminogen activator, and drugs that reduce swelling such as mannitol or corticosteroids. The Merck Manual of Medical Information 352-355 (R. Berkow ed., 1997).

Pruritus is an unpleasant sensation that prompts scratching. Pruritus can be attributed to dry skin, scabies, dermatitis, herpetiformis, atopic dermatitis, pruritus vulvae et ani, miliaria, insect bites, pediculosis, contact dermatitis, drug reactions, urticaria, urticarial eruptions of pregnancy, psoriasis, lichen planus, lichen simplex chronicus, exfoliative dermatitis, folliculitis, bullous pemphigoid, and fiberglass dermatitis.
Conventionally, pruritus is treated by phototherapy with ultraviolet B or PUVA or with therapeutic agents such as naltrexone, nalmefene, danazol, tricyclics, and antidepressants.
Selective antagonists of the metabotropic glutamate receptor 5 ("mGluR5") have been shown to exert analgesic activity in in vivo animal models (K.
Walker et al., Neuropharmacology 40:1-9 (2000) and A. Dogrul et al., Neuroscience Letters, 292(2):115-118 (2000)).

Selective antagonists of the mGluR5 receptor have also been shown to exert anxiolytic and anti-depressant activity in in vivo animal models (E.
Tatarczynska et al., Br. J.
Pharmacol. 132(7):1423-1430 (2001) and P.J.M. Will et al., Trends in Pharmacological Sciences 22(7):331-37 (2001)).
Selective antagonists of the mGluR5 receptor have also been shown to exert anti-Parkinson activity in vivo (K. J. Ossowska et al., Neuropharmacology 41(4):413-20 (2001) and P.J.M. Will et al., Trends in Pharmacological Sciences 22(7):331-37 (2001)).

Selective antagonists of the mGluR5 receptor have also been shown to exert anti-dependence activity in vivo (C. Chiamulera et al., Nature Neuroscience 4(9):873-74 (2001)).

U.S. Patent No. 6,150,129 to Cook et al. describes a class of dinitrogen heterocycles useful as antibiotics.

U.S. Patent No. 5,529,998 to Habich et al. describes a class of benzooxazolyl-and benzothiazolyloxazolidones useful as antibacterials.

International publication no. WO 01/57008 describes a class of 2-benzothiazolyl urea derivatives useful as inhibitors of serine/threonine and tyrosine kinases.
International publication no. WO 02/08221 describes aryl piperazine compounds useful for treating chronic and acute pain conditions, itch, and urinary incontinence.

International publication no. WO 99/37304 describes substituted oxoazaheterocycly compounds useful for inhibiting factor Xa.

International publication no. WO 00/59510 describes aminopyrimidines useful as sorbitol dehydrogenase inhibitors.
Japanese patent application no. 11-199573 to Kiyoshi et al. describes benzothiazole derivatives that are neuronal 5HT3 receptor agonists in the intestinal canal nervous system and useful for treating digestive disorders and pancreatic insufficiency.

German patent application no 199 34 799 to Rainer et al. describes a chiral-smectic liquid crystal mixture containing compounds with 2 linked (hetero)aromatic rings or compounds with 3 linked (hetero)aromatic rings.

M. Chu-Moyer et al., J. Med. Cliem. 45:511-528 (2002) describes heterocycle-substituted piperazino-pyrimidines useful as sorbitol dehydrogenase inhibitors.

B.G. Khadse et al., Bull. Haff. Instt. 1(3):27-32 (1975) describes 2-(N4-substituted-N'-piperazinyl) pyrido(3,2-d)thiazoles and 5-nitro-2-(N4-substituted-N'-piperazinyl)benzthiazoles useful as anthelmintic agents.

There remains, however, a clear need in the art for new drugs useful for treating or preventing pain, UT, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, ALS, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression.

Citation of any reference in Section 2 of this application is not to be construed as an admission that such reference is prior art to the present application.

3. SUMMARY OF THE INVENTION
The present invention encompasses compounds having the formula (la):
Ari Nl J (Rs)m N

()x N
S
(Ia) and pharmaceutically acceptable salts thereof, wherein Arl is (R2)n (R2)p N

R1 iN or R1 iN
A is O N- or S N-R, is -Cl, -Br, -I, -(C1-C6)alkyl, -NO2, -CN, -OH, -OCH3, -NH2, -C(halo)3, -CH(halo)2, or -CH2(halo);

each R2 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;

(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C$ C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;

each R3 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(CZ C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(CS
C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8 C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
R4 is -H or -(C1-C6)alkyl;
each R5 is independently -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R6 is independently -(C-C6)alkyl, -(CZ C6)alkenyl, -(CZ C6)alkynyl, -(C3 C3)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R7 is independently -H, -(C1-C6)alkyl, -(CZ C6)alkenyl, -(CZ C6)alkynyl, -(C3--C8)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -(C3 C5)heterocycle, -C(halo)3, -CH2(halo), or -CH(halo)2;
R8 and R9 are each independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(CZ C6)alkynyl, -(C3 C8)cycloalkyl, -(CS C3)cycloalkenyl, -phenyl, -C(halo)3, -CH(halo)2, -CH2(halo), -OC(halo)3, -OCH(halo)2, -OCH2(halo), -CN, -OH, -halo, -N3, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;

each -halo is -F, -Cl, -Br,- or -I;

n is an integer ranging from 0 to 3;
p is an integer ranging from 0 to 2;
mis0or1;and xis0or1.
The present invention encompasses compounds having the formula (lb):
Art J (R3)m N

(A)x N
S

(Ib) and pharmaceutically acceptable salts thereof, wherein Arl is (R2)p (R2)p N~~ I " N
R N R1 iN R1 or A is O
NR4 _ or S _ R1 is -H, -halo, -(C1-C6)alkyl, -NO2, -CN, -OH, -OCH31-NH21 -C(halo)3, -CH(halo)2, or -CH2(halo);

each R2 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;

(b) -(C1-C10)alky1, -(C2-C10)alkenyl, -(Cz C10)alkynYl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
each R3 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(CZ C10)alkynyl, -(C3-C10)cycloalkyl, -(C$ C14)bicycloalkyl, -(C8 C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C$
C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
R4 is -H or -(C1-C6)alkyl;
each R5 is independently -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R6 is independently -(Ci C6)alkyl, -(C2 C6)alkenyl, -(CZ C6)alkynyl, -(C3 C8)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -(C3 C)heterocycle, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R7 is independently -H, -(CI-C6)alkyl, -(C2 C6)alkenyl, -(C2 C6)alkynyl, -(C3 C8)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -(C3 C5)heterocycle, -C(halo)3, -CH2(halo), or -CH(halo)2;
R8 and R9 are each independently -H, -(Cl C6)alkyl, -(CZ C6)alkenyl, -(CZ C6)alkynyl, -(C3 C8)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -C(halo)3, -CH(halo)2, -CH2(halo), -OC(halo)3, -OCH(halo)2, -OCH2(halo), -CN, -OH, -halo, -N3, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each -halo is -F, -Cl, -Br,- or -I;
p is an integer ranging from 0 to 2;
mis0or1;and xis0or1.
The present invention encompasses compounds having the formula (IIa):
Art (R3)m N

R$ R9 (Ha) and pharmaceutically acceptable salts thereof, wherein Art is (R2)n (R2)p N (R2)p R1 I ,N R R iN

or R1 is -Cl, -Br, -I, -(C1-C6)alkyl, -NO2, -CN, -OH, -OCH3, -NH21 -C(halo)3, -CH(halo)2, or -CH2(halo);

each R2 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C$ C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8 C14)bicycloalkenyl, -(C$ C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;

each R3 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;

each R5 is independently -CN, -OH, -halo, -N31 -NO2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R6 is independently -(C1-C6)alkyl, -(C2 C6)alkenyl, -(Cz C6)alkynyl, -(C3 C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3 C5)heterocycle, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R7 is independently -H, -(Ci C6)alkyl, -(C2--C6)alkenyl, -(CZ C6)alkynyl, -(C3 C8)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -(C3 C5)heterocycle, -C(halo)3, -CH2(halo), or -CH(halo)2;

R8 and R9 are each independently -H, -(Ci C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3 C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -C(halo)3, -CH(halo)2, -CH2(halo), -OC(halo)3, -OCH(halo)2, -OCH2(halo), -CN, -OH, -halo, -N3,-N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
R10 is -H or -(C1-C4)alkyl;

each -halo is -F, -Cl, -Br,- or -I;

n is an integer ranging from 0 to 3;
p is an integer ranging from 0 to 2; and mis0or1.
The present invention encompasses compounds having the formula (IIb):
Ar1 Nl J (R3)m N
(A)x `-R10 N N

(]E[b) and pharmaceutically acceptable salts thereof, wherein Arl is (R2)p N N-S
\ I ,N

or A is O
NR4 _ or S _ R, is -H, -halo, -(C1-C6)alkyl, -NO2, -CN, -OH, -OCH3, -NH2, -C(halo)3, -CH(halo)2, or -CH2(halo);

each R2 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C,0)alkynyl, -(C3-C10)cycloalkyl, -(C$ C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C$ C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
each R3 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8 C14)bicycloalkyl, -(Cg-C14)tricycloalkyl, -(CS
C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C$ C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
R4 is -H or -(C1-C6)alkyl;
each R5 is independently -CN, -OH, -halo, -N3, -NO2, -CH NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R6 is independently -(Ci C6)alkyl, -(CZ C6)alkenyl, -(CZ C6)alkynyl, -(C3 C8)cycloalkyl, -(C5 Cg)cycloalkenyl, -phenyl, -(C3 C5)heterocycle, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -NO2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R7 is independently -H, -(C1_C6)alkyl, -(CZ C6)alkenyl, -(C2 C6)alkynyl, -(C3 C8)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -(C3 C5)heterocycle, -C(halo)3, -CH2(halo), or -CH(halo)2;
R8 and R9 are each independently -H, -(Ci C6)alkyl, -(Cz C6)alkenyl, -(Cz C6)alkynyl, -(C3 C8)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -C(halo)3, -CH(halo)2, -CH2(halo), -OC(halo)3, -OCH(halo)2, -OCH2(halo), -CN, -OH, -halo, -N31 -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
R10 is -H or -(C1-C4)alkyl;
each -halo is -F, -Cl, -Br,- or -I;
p is an integer ranging from 0 to 2;
misOor1;and xis0or1.
The present invention encompasses compounds having the formula (IIIa):
Art N"~
J (R3)m N

(A)x N`
O

(IIIa) and pharmaceutically acceptable salts thereof, wherein Art is (R2)n (R2)p RI iN or R1 iN
A is O or S_'T.

R1 is -Cl, -Br, -I, -(C1-C6)alkyl, -NO2, -CN, -OH, -OCH31 -NH21 -C(halo)31 -CH(halo)2, or -CH2(halo);

each R2 is independently:

(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2 C10)alkenyl, -(CZ C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;

each R3 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(Cg C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8 C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
R4 is -H or -(C1-C6)alkyl;
each R5 is independently -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R6 is independently -(Ci C6)alkyl, -(Cz C6)alkenyl, -(CZ C6)alkynyl, -(C3 C8)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -(C3 C5)heterocycle, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R7 is independently -H, -(Ci C6)alkyl, -(CZ C6)alkenyl, -(C2 C6)alkynyl, -(C3 C8)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH2(halo), or -CH(halo)2;

R8 and R9 are each independently -H, -(Ci C6)alkyl, -(C2 C6)alkenyl, -(C2 C6)alkynyl, -(C3 C8)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -C(halo)3, -CH(halo)2, -CH2(halo), -OC(halo)3, -OCH(halo)2, -OCH2(halo), -CN, -OH, -halo, -N3, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each -halo is -F, -Cl, -Br,- or -I;

n is an integer ranging from 0 to 3;
p is an integer ranging from 0 to 2;
m is 0 or 1; and xis0or1.
The present invention encompasses compounds having the formula (Mb):
Art (R3)m N

N:kA)x O

(11th) and pharmaceutically acceptable salts thereof, wherein Ari is (R2)p (R2)p N~~ N N
i N R1 N R1 R1 , or A is 0-T or S _ R1 is -H, -halo, -(C1-C6)alkyl, -NO2, -CN, -OH, -OCH31 -NH2, -C(halo)3, -CH(halo)2, or -CH2(halo);
each R2 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C 14)tricycloalkenyl, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, or-(C14)aryl each of which is unsubstituted or substituted with one or more R6 groups;

each R3 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(CZ C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C 14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C
10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
R4 is -H or -(C1-C6)alkyl;
each R5 is independently -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R6 is independently -(C,-C6)alkyl, -(CZ C6)alkenyl, -(Cz C6)alkynyl, -(C3 C8)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -(C3 C5)heterocycle, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R7 is independently -H, -(C1-C6)alkyl, -(C2 C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3 C5)heterocycle, -C(halo)3, -CH2(halo), or -CH(halo)2;

R8 and R9 are each independently -H, -(C1-C6)alkyl, -(Cz C6)alkenyl, -(C2 C6)alkynyl, -(C3 C3)cycloalkyl, -(CS C$)cycloalkenyl, -phenyl, -C(halo)3, -CH(halo)2, -CH2(halo), -OC(halo)3, -OCH(halo)2, -OCH2(halo), -CN, -OH, -halo, -N31 -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each -halo is -F, -Cl, -Br,- or -I;
p is an integer ranging from 0 to 2;
mis0or1;and xis0or1.
The present invention also encompasses compounds having the formula (Na):
Art N

HN "ILO

Are (Na) and pharmaceutically acceptable salts thereof, wherein Arl is (R2)n (R2)p N
IX I
R1 N or R1 N
Ar2 is J~" ill, Irv%IVV
N
S N NJ NH
R8 R9 a R8 R9 a or R8 R9 R1 is -halo, -(C1-C6)alkyl, -NO2, -CN, -OH, -OCH31 -NH21 -C(halo)3, -CH(halo)2, or -CH2(halo);
each R2 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8 C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;

R3 is -H or -CH3:
each R5 is independently -CN, -OH, -halo, -N31 -NO2, -N(R7)2, -CH=NR,, -NR7OH, -OR,, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R6 is independently -(CI_C6)alkyl, -(C2-C6)alkenyl, -(Cz C6)alkynyl, -(C3 C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3 C5)heterocycle, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R7 is independently -H, -(Ci C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3 C8)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -(C3 C5)heterocycle, -C(halo)3, -CH2(halo), or -CH(halo)2;
R8 and R9 are each independently -H, -(Ci C6)alkyl, -(CZ C6)alkenyl, -(Cz C6)alkynyl, -(C3 C8)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -C(halo)3, -CH(halo)2, -CH2(halo), -OC(halo)3, -OCH(halo)2, -OCH2(halo), -CN, -OH, -halo, -N3, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;

each -halo is -F, -Cl, -Br,- or -I;
n is an integer ranging from 0 to 3; and p is an integer ranging from 0 to 2.
The present invention also encompasses compounds having the formula (Nb):
A r1 I
(I )X

Are (IVb) and pharmaceutically acceptable salts thereof, wherein Art is (R2)n (R2)p I
R N or R1 N

Ar2 is Ni Ni S O N NH
R8 R9 R8 R9 , or R8 R9 A is or g O N-R1 is -halo, -(C1-C6)alkyl, -NO2, -CN, -OH, -OCH3, -NH2, -C(halo)3, -CH(halo)2, or -CH2(halo);
each R2 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenYl, -(Ci C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8 C14)tricycloalkyl, -(CS
C10)cycloalkenyl,-(C8 C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
R3 is -CH3;
R4 is -H or -(C1-C6)alkyl;
each R5 is independently -CN, -OH, -halo, -N31 -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R6 is independently -(Ci C6)alkyl, -(Cz C6)alkenyl, -(C2 C6)alkynyl, -(C3 C8)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -(C3 C5)heterocycle, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R7 is independently -H, -(C1-C6)alkyl, -(CZ C)alkenyl, -(C2 C6)alkynyl, -(C3 C8)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH2(halo), or -CH(halo)2;
R8 and R9 are each independently -H, -(C1-C6)alkyl, -(CZ C6)alkenyl, -(Cz C6)alkynyl, -(C3 C8)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -C(halo)3, -CH(halo)2, -CH2(halo), -OC(halo)3, -OCH(halo)2, -OCH2(halo), -CN, -OH, -halo, -N3, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each -halo is -F, -Cl, -Br,- or -I;
n is an integer ranging from 0 to 3;

p is an integer ranging from 0 to 2; and xis0or1.
The present invention also encompasses compounds having the formula (V):

Arl N
s Are (V) and pharmaceutically acceptable salts thereof, wherein Art is (R2)n (R2)p I~ I 1 R1 N or Ri N

Are is wvw niwo _ Ni`

R8 R9 R8 R9 , or R

R1 is -halo, -(C1-C6)alkyl, -NO2, -CN, -OH, -OCH31 -NH21 -C(halo)3, -CH(halo)2, or -CH2(halo);

each R2 is independently:

(a) -halo, -CN, -OH, -O(C1-C6)alkyl, =N021 or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C3-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C$ C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;

R3 is -H or -CH3:
each R5 is independently -CN, -OH, -halo, -N3, -NO2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R6 is independently -(Ci C6)alkyl, -(C2 C6)alkenyl, -(CZ C6)alkynyl, -(C3 C8)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N31 -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R7 is independently -H, -(Ci C6)alkyl, -(C2 C6)alkenyl, -(C2 C6)alkynyl, -(C3 C8)cycloalkyl, -(CS C8)cycloalkenyl, -phenyl, -(C3 C5)heterocycle, -C(halo)3, -CH2(halo), or -CH(halo)2;
R8 and R9 are each independently -H, -(C1_C6)a1ky1, -(CZ C6)alkenyl, -(CZ C6)alkynyl, -(C3 C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -C(halo)3, -CH(halo)2, -CH2(halo), -OC(halo)3, -OCH(halo)2, -OCH2(halo), -CN,. -OH, -halo, -N3, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each -halo is -F, -Cl, -Br,- or -I;

n is an integer ranging from 0 to 3; and p is an integer ranging from 0 to 2.
A compound of formula (Ia), (Ib), (IIa), (11b), (Ma), (IIIb), (IVa), (IVb), and (V) or a pharmaceutically acceptable salt thereof (a "Benzoazolylpiperazine Compound") is useful for treating or preventing pain, UT, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, ALS, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal.
The invention also relates to compositions comprising an effective amount of a Benzoazolylpiperazine Compound and a pharmaceutically acceptable carrier or excipient.
The compositions are useful for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, ALS, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal.

The invention further relates to methods for treating pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, ALS, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression comprising administering to an animal in need thereof an effective amount of a Benzoazolylpiperazine Compound.

The invention further relates to methods for preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, ALS, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression comprising administering to an animal in need thereof an effective amount of a Benzoazolylpiperazine Compound.

The invention still further relates to methods for inhibiting Vanilloid Receptor 1 ("VRl") function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of a Benzoazolylpiperazine Compound.

The invention still further relates to methods for inhibiting mGluR5 function in a cell, comprising contacting a cell capable of expressing mGluR5 with an effective amount of a Benzoazolylpiperazine Compound.

The invention still further relates to methods for inhibiting metabotropic glutamate receptor 1 ("mGluRl") function in a cell, comprising contacting a cell capable of expressing mGluR1 with an effective amount of a Benzoazolylpiperazine Compound.

The invention still further relates to a method for preparing a composition comprising the step of admixing a Benzoazolylpiperazine Compound and a pharmaceutically acceptable carrier or excipient.
The invention still further relates to a kit comprising a container containing an effective amount of a Benzoazolylpiperazine Compound.
The present invention still further relates to a compound selected from the group consisting of CI iN CI iN CII iN
N) (N) N
C
N N
N
HN'~O HN"O HNAO
S- ~,\ N S4 N S- \\N

CI , CH3CH2O F3C
\
~ \ \
CF3 i N CF I N CI I i N

)..4,*C N
N H3 (N),,4" N CH3 N CH3 HNO HN~O HN"'~O
S-\\N S-\~ S-\\
N N
' CH3 CH3 N I \ I \
CI i Cl N CI ,,,q N
(N) N
N (N)""* N CH3 N-N O
HN HN~O
S' \\N S4 S4 d N N 'd d CH3 Br CI iN CI g"'N CI I iN
CN
N~CH3 (C N).."", N
HN O HN^` O HN O

S \ N S- ~x N S4N

CI CF3 xd p d CI iN CI iN H C I iN

N
C(N)"4v*

N CH3 ~ CH3 HN O H~(N O HN O
S/\\N S~\\ S /\
N \N
F

iN

(N., C N

N CH3 ~~CH3 CH3 (CH3)2CH (CH3)3C
and pharmaceutically acceptable salts thereof.
The present invention still further relates to a compound selected from the group consisting of PN ~
I iN
N CI CI
CJ N
N (N) (N)--"CH3 HN O
HN O H N O
N
N-H
N RN-H N -,~ N-H
C(CH3)3 ' CH3 CH3 CI i N CI i N
CI 9N (N)..
N N
CN='CHC:CH3 C
N
"~ N HN O HN O HNO

N %~N /\
N N-H W,4 N-CH3 C H3 CH3 C(CH3)3 CH3 CH3 N !N N
CI
C1 CI !
N
N
).""CH3 C:) ~ ~ H NO
H'N O HN
%~ N~N-H

' (CH3)3C C(CH3)3 C(CH3)3 I !N N
N
Cl Cl I ! CH3 N
N N

C ~ CNCH3 NCH3 N CH3 "~
HN O
HN'k-O HN O
%\ N~N_.H
N N-CH3 N N-CHa /

' (CH3)3C C(CH3)3 (CH3)3 C
\
!
!N N Cl N (CH3 25 CNCH3 CNCH3 O
HN O HNO HN

N%\ Ni\N-H N-H
N--H

C(CH3)3 CI OCH3 and pharmaceutically acceptable salts thereof.

The present invention still further relates to a compound selected from the group consisting of CI i N

CN N~ N CH3 (N) N
HN O
HN O
N/ N-(CH3)3C
(CH3)3C
and pharmaceutically acceptable salts thereof.

The present invention can be understood more fully by reference to the following detailed description and illustrative examples, which are intended to exemplify non-limiting embodiments of the invention.
4. DETAILED DESCRIPTION OF THE INVENTION

4.1 The Compounds of Formula Ua) As stated above, the present invention encompasses compounds of Formula (la) Art "~
(R3)m N
(A)x N S

(Ia) and pharmaceutically acceptable salts thereof, where Arl, R3, R8, R9, A, x, and in, are defined above for the Benzoazolylpiperazine Compounds of formula (Ia).
In one embodiment, Arl is a pyridyl group.
In another embodiment, Ar1 is a pyrimidinyl group.
In another embodiment, x is 1 and A is -C(O)-N(R4)-.
In another embodiment, x is 1 and A is -C(S)-N(R4)-.
In another embodiment x is 0.

In another embodiment, n or p is 0.
In another embodiment, n or p is 1.
In another embodiment, in is 0.

In another embodiment, in is 1.
In another embodiment, R4 is -H.
In another embodiment, R4 is -(C1-C6)alkyl.
In another embodiment, Arl is a pyridyl group, x is 1, and A is -C(O)N(R4)-.
In another embodiment, Art is a pyridyl group, x is 1, and A is -C(S)N(R4)-.
In another embodiment, Art is a pyrimidinyl group, x is 1, and A is -C(O)N(R4)-.
In another embodiment, Arl is a pyrimidinyl group, x is 1, and A is -C(S)N(R4)-.

In another embodiment, R1 is -Cl.
In another embodiment, R1 is -Br.
In another embodiment, R1 is -I.
In another embodiment, R1 is -(C1-C6)alkyl.
In another embodiment, R1 is -CH3.

In another embodiment, R1 is -NO2.
In another embodiment, R1 is -CN.
In another embodiment, R1 is -OH.

In another embodiment, R1 is -OCH3.
In another embodiment, R1 is -NH2.
In another embodiment, R1 is -C(halo)3.
In another embodiment, R1 is -CH(halo)2.
In another embodiment, R1 is -CH2(halo).

In another embodiment, n and p are 1 and R2 is -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2.

In another embodiment, n and p are 1 and R2 is -(C1-C10)alkyl, -(C2-C10)alkenyl, -(Cz C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3-to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups.

In another embodiment, n and p are 1 and R2 is -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;

In another embodiment, m is 1 and R3 is -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2.

In another embodiment, m is 1 and R3 is -(C1-C10)alkyl, -(C2-C10)alkenyl, -(CZ
C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)triCycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups.
In another embodiment, m is 1 and R3 is -phenyl, -naphthyl, -(C14)aryl or -(5-to 1 0-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups.
In another embodiment, R8 and R9 are each independently -H, -halo, -(C1-C6)alkyl, -O(C1-C6)alkyl, -C(halo)3, -CH(halo)2, or -CH2(halo).
In another embodiment, at least one of R8 and R9 is -H.
In another embodiment, n, p, and m are 0; R1 is -Cl, -Br, or, -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; and R8 and R9 are -H.
In another embodiment, n, p, and m are 0; R1 is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, and R8 and R9 are -H.

In another embodiment, n, p, and m are 0; R1 is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -H; and R9 is -halo. In another embodiment, R1 is -Cl. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, n, p, and m are 0; R1 is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R1 is -Cl. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, n, p, and m are 0; R1 is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -halo; and R9 is -H. In another embodiment, R1 is -Cl. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R. is -F.
In another embodiment, n, p, and m are 0; R1 is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R1 is -Cl. In another embodiment, R. is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.
In another embodiment, n, p, and m are 0; R1 is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -H; and R9 is -CH3.

In another embodiment, n, p, and m are 0; R1 is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CH3.

In another embodiment, n, p, and m are 0; R1 is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -CH3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CH3, and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -H; and R9 is -CF3.
In another embodiment, n, p, and m are 0; R, is -Cl; x is 1; A is -C(O)-N(R4)-;
R4 is -H; R8 is -H; and R9 is -CF3.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -CF3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl; x is 1; A is -C(O)-N(R4)-;
R4 is -H; R8 is -CF3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -H; and R9 is -OCH2CH3.
In another embodiment, n, p, and m are 0; R, is -Cl; x is 1; A is -C(O)-N(R4)-;
R4 is -H; R3 is -H; and R9 is -OCH2CH3.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl; x is 1; A is -C(O)-N(R4)-;
R4. is -H; R3 is -OCH2CH3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -CH3; x is 1; A is -C(O)-N(R4)-; R4 is -H; and R8 and R9 are -H.
In another embodiment, n, p, and m are 0; R, is -CH3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -H; and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, n, p, and m are 0; R, is -CH3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -halo; and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.

In another embodiment, n, p, and m are 0; R, is -CH3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -H; and R9 is -CH3.
In another embodiment, n, p, and m are 0; R, is -CH3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -CH3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -CH3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -H; and R9 is -CF3.
In another embodiment, n, p, and m are 0; R, is -CH3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -CF3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -CH3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -H; and R9 is -OCH2CH3.
In another embodiment, n, p, and m are 0; R, is -CH3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -CF3; x is 1; A is -C(O)-N(R4)-; R4 is -H; and R8 and R9 are -H.
In another embodiment, n, p, and m are 0; R, is -CF3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -H; and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, n, p, and m are 0; R, is -CF3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -halo; and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.
In another embodiment, n, p, and m are 0; R, is -CF3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -H; and R9 is -CH3.
In another embodiment, n, p, and m are 0; R, is -CF3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -CH3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -CF3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -H; and R9 is -CF3.
In another embodiment, n, p, and m are 0; R, is -CF3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -CF3; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -CF3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -H; and R9 is -OCH2CH3.

In another embodiment, n, p, and m are 0; R, is -CF3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -tent-butyl; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl; x is 1; A is -C(O)-N(R4)-;
R4 is -H; R8 is -tert-butyl; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is R, is -Cl, -Br, or -I; x is 1;
A is -C(O)-N(R4)-; R4 is -H; R8 is -H; and R9 is -tert-butyl.
In another embodiment, n, p, and m are 0; R, is R, is -Cl; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -H; and R9 is -tert-butyl.
In another embodiment, n, p, and m are 0; R, is -CH3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -tert-butyl; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -CH3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -H; and R9 is -tert-butyl.
In another embodiment, n, p, and m are 0; R, is -CH3; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -CH3; and R9 is -CH3.
In another embodiment, n is 0, Art is -2-(3-nitropyridyl)-, m is 0, x is 0, and R8 and R9 are -H.
In another embodiment, n is 0, Art is -2-(3-chloropyridyl)-, x is 1, A is -C(S)-N(R4)-, m is 1, R3 is -CH3, R3 is attached to the carbon atom adjacent to the nitrogen attached to the -C(SO)-N(R4)- group, the carbon atom to which the R3 group is attached has the R
configuration, R8 is -H, and R9 is -CH3.
In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; x is 1; A
is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, m is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; x is 1; A
is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R8 is -H; and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. . In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, m is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R$ is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; x is 1; A
is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R8 is -halo; and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, m is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -halo, and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S

configuration.
In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; x is 1; A
is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R8 is -H; and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 1;
A is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R8 is -CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 1;
A is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R8 is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 1;
A is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R8 is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, m is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I. x is 1;
A is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R8 is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 1;
A is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R8 is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -halo, and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -halo, and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CF3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R$ is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, in is 1, R, is -CF3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, in is 1, R, is -CF3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration.

In another embodiment, n and p are 0, in is 1, R, is -CF3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R$ is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CF3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R$ is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 1;
A is -C(O)-N(R4)-; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R4 is -H; R8 is -tert-butyl; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 1;
A is -C(O)-N(R4)-; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R4 is -H; R8 is -H; and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -CH3, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or, -I; x is 0; R4 is -H;
and R8 and R9 are -H.
In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; and R8 and R9 are -H.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or, -I; x is 0; R4 is -H;
R8 is -H; and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; R8 is -H;
and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or, -I. x is 0; R4 is -H;
R8 is -halo; and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.
In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; R8 is -halo; and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or, -I. x is 0; R4 is -H;
R8 is -H; and R9 is -CH3.

In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; R8 is -H;
and R9 is -CH3.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or, -I; x is 0; R4 is -H;
R8 is -CH3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; R8 is -CH3; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or, -I; x is 0; R4 is -H;
R8 is -H; and R9 is -CF3.
In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; R8 is -H;
and R9 is -CF3.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or, -I; x is 0; R4 is -H;
R8 is -CF3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; R8 is -CF3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or, -I; x is 0; R4 is -H;
R8 is -H; and R9 is -OCH2CH3.

In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; R8 is -H;
and R9 is -OCH2CH3.

In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or, -I; x is 0; R4 is -H;
R8 is -OCH2CH3; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; R8 is -OCH2CH3; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -CH3; x is 0; R4 is -H; and R8 and R9 are -H.

In another embodiment, n, p, and m are 0; R, is -CH3; x is 0; R4 is -H; R8 is -H; and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, n, p, and m are 0; R, is -CH3; x is 0; R4 is -H; R8 is -halo; and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.

In another embodiment, n, p, and m are 0; R, is -CH3; x is 0; R4 is -H; R8 is -H; and R9 is -CH3.

In another embodiment, n, p, and m are 0; R, is -CH3; x is 0; R4 is -H; R8 is -CH3; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -CH3; x is 0; R4 is -H; R8 is -H; and R9 is -CF3.

In another embodiment, n, p, and m are 0; R, is -CH3; x is 0; R4 is -H; R8 is -CF3; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -CH3; x is 0; R4 is -H; R8 is -H; and R9 is -OCH2CH3.
In another embodiment, n, p, and m are 0, R, is -CH3; x is 0; R4 is -H; R8 is -OCH2CH3; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -CF3; x is 0; R4 is -H; and R8 and R9 are -H.

In another embodiment, n, p, and m are 0; R, is -CF3; x is 0; R4 is -H; R3 is -H;
and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, n, p, and m are 0; R, is -CF3; x is 0; R4 is -H; R8 is -halo; and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R3 is -F.

In another embodiment, n, p, and m are 0, R, is -CF3; x is 0; R4 is -H; R8 is -H;
and R9 is -CH3.

In another embodiment, n, p, and m are 0; R, is -CF3; x is 0; R4 is -H; R8 is -CH3; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -CF3; x is 0; R4 is -H; R8 is -H;
and R9 is -CF3.

In another embodiment, n, p, and m are 0; R, is -CF3; x is 0; R4 is -H; R8 is -CF3; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -CF3; x is 0; R4 is -H; R8 is -H;
and R9 is -OCH2CH3.

In another embodiment, n, p, and m are 0; R, is -CF3; x is 0; R4 is -H; R8 is -OCH2CH3; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or, -I; x is 0; R4 is -H;
R8 is -tert-butyl; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; R8 is -tert-butyl; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or, -I; x is 0; R4 is -H;
R8 is -H; and R9 is -tert-butyl.

In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; R8 is -H;
and R9 is -tert-butyl.
In another embodiment, n, p, and in are 0; R, is -CH3; x is 0; R4 is -H; R3 is -tert-butyl; and R9 is -H.
In another embodiment, n, p, and in are 0; R, is -CH3; x is 0; R4 is -H; R$ is -H; and R9 is -tert-butyl.
In another embodiment, n, p, and in are 0; R, is -CH3; x is 0; R4 is -H; R8 is -CH3; and R9 is -CH3.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 0;
R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; and R3 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl; x is 0; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 0;
R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R$ is -H; and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R3 is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 0;
R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R$ is -halo; and R9 is -H. In another embodiment R$ is -Cl. In another embodiment, R3 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, m is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -halo, and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R$ is -Br. In another embodiment, R$ is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; x is 0;
R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R$ is -H; and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration.

In another embodiment, n and p are 0, m is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R$ is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration.

In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; x is 0;
R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R$ is -CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R3 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; x is 0;
R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R8 is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 0;
R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R8 is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 0;
R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R8 is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; x is 0;
R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R8 is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R3 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, and R3 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R$ is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -halo, and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R3 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R$ is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -CH31 and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R, is -CH3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R, is -CH31 x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R, is -CF3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R, is -CF31 x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -halo, and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, in is 1, R, is -CF3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, in is 1, R, is -CF3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -CF31 and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 0;
R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R4 is -H; R8 is -tert-butyl; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -tent-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or, -I; x is 0;
R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R4 is -H; R8 is -H; and R9 is -tent-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, m is 1, R, is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R3 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -CH3, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; in is 1; R, is -CH31 -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R4 is -H; R8 is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyridyl group; n is 0; in is 1; R, is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R4 is -H; R8 is -H; and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridyl group, n is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R$ is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Arl is a pyridyl group, n is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Arl is a pyrimidinyl group; p is 0; in is 1; R, is --Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R4 is -H; R$ is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R$ is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrimidinyl group; p is 0; in is 1; R, is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R4 is -H; R$ is -H; and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Arl is a pyrimidinyl group, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a pyridyl group; n is 0; in is 1; R, is -CH3, -Cl, -Br, or -I; x is 0; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R4 is -H; R8 is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridyl group, n is 0, in is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group; n is 0; in is 1; R, is -Cl, -Br, or -I; x is 0; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R4 is -H; R8 is -H; and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridyl group, n is 0, in is 1, R, is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0, in is 1, R, is -CH31 x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Arl is a pyrimidinyl group; p is 0; in is 1; Rt is --Cl, -Br, or -I; x is 0; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R4 is -H; R3 is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0, in is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyrimidinyl group; p is 0; in is 1; Rt is -Cl, -Br, or -I; x is 0; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R4 is -H; R8 is -H; and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0, in is 1, Rt is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0, in is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzothiazolyl group when x is 0. In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzothiazolyl group when x is 0 and the carbon to which the R3 group is attached is in the R configuration.
In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzothiazolyl group when x is 0. In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzothiazolyl group when x is 0 and the carbon to which the R3 group is attached is in the R
configuration.

In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzothiazolyl group when x is 0. In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzothiazolyl group when x is 0 and the carbon to which the R3 group is attached is in the S configuration.
In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzothiazolyl group when x is 0. In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzothiazolyl group when x is 0 and the carbon to which the R3 group is attached is in the S
configuration.

In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group. In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group and the carbon to which the R3 group is attached is in the R configuration.

In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group. In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group and the carbon to which the R3 group is attached is in the R configuration.
In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group. In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group and the carbon to which the R3 group is attached is in the S configuration.
In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group. In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group and the carbon to which the R3 group is attached is in the S configuration.

4.2 The Compounds of Formula (Ibl The present invention also encompasses compounds of formula (Ib):
Art (R36 NJ

(A)x N
S
O

(Ib) and pharmaceutically acceptable salts thereof, where Art, R3, R8, R9, A, x, and in, are defined above for the Benzoazolylpiperazine Compounds of formula (Ib).

In one embodiment, Art is a pyrazinyl group.

In another embodiment, Art is a pyridazinyl group.
In another embodiment, Art is a thiazanyl group.
In another embodiment, x is 1 and A is -C(O)-N(R4)-.
In another embodiment, x is 1 and A is -C(S)-N(R4)-.
In another embodiment x is 0.
In another embodiment, p is 0.
In another embodiment, p is 1.
In another embodiment, m is 0.
In another embodiment, m is 1.
In another embodiment, R4 is -H.

In another embodiment, R4 is -(C1-C6)alkyl.

In another embodiment, Art is a pyrazinyl group, x is 1, and A is -C(O)N(R4)-.
In another embodiment, Art is a pyrazinyl group, x is 1, and A is -C(S)N(R4)-.
In another embodiment, Art is a pyridazinyl group, x is 1, and A is -C(O)N(R4)-.
In another embodiment, Art is a pyridazinyl group, x is 1, and A is -C(S)N(R4)-.
In another embodiment, Art is a thiazanyl group, x is 1, and A is -C(O)N(R4)-.
In another embodiment, Art is a thiazanyl group, x is 1, and A is -C(S)N(R4)-.
In another embodiment, R1 is -H.
In another embodiment, R1 is -Cl.
In another embodiment, R1 is -Br.
In another embodiment, R1 is -I.

In another embodiment, R1 is -F.

In another embodiment, R1 is -(C1-C6)alkyl.
In another embodiment, R1 is -CH3.
In another embodiment, R1 is -NO2.
In another embodiment, R1 is -CN.
In another embodiment, R1 is -OH.

In another embodiment, R1 is -OCH3.
In another embodiment, R1 is -NH2.

In another embodiment, R1 is -C(halo)3.
In another embodiment, R1 is -CH(halo)2.
In another embodiment, R1 is -CH2(halo).
In another embodiment, p is 1 and R2 is -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, -NH2.
In another embodiment, p is 1 and R2 is -(C,-C10)alkyl, -(Cz C10)alkenyl, -(CZ
C10)alkynyl, -(C3-C10)cycloalkyl, -(C$ C,4)bicycloalkyl, -(C8 C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8 C14)bicycloalkenyl, -(C8 C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups.
In another embodiment, p is 1 and R2 is -phenyl, -naphthyl, -(C14)aryl, or -(5-to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups.
In another embodiment, m is 1 and R3 is -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, -NH2.
In another embodiment, m is 1 and R3 is -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C$ C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups.
In another embodiment, m is 1 and R3 is -phenyl, -naphthyl, -(C14)aryl or -(5-to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups.
In another embodiment, R8 and R9 are each independently -H, halo, -(C1-C6)alkyl, -O(C1-C6)alkyl, -C(halo)3, -CH(halo)2, or -CH2(halo).
In another embodiment, at least one of R8 or R9 is -H.
In another embodiment, p and m are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, and R8 and R9 are -H.

In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, and R8 and R9 are -H.

In another embodiment, p and m are 0, R1 is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, p and m are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.

In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.

In another embodiment, p and m are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CH3.

In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CH3.

In another embodiment, p and m are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CH3, and R9 is -H.

In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CH3, and R9 is -H.

In another embodiment, p and m are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CF3.

In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CF3.

In another embodiment, p and m are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CF3, and R9 is -H.

In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CF3, and R9 is -H.

In another embodiment, p and m are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -OCH2CH3.

In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -OCH2CH3.

In another embodiment, p and m are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -OCH2CH3, and R9 is -H.
In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -OCH2CH3, and R9 is -H.
In another embodiment, p and m are 0, R, is. -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, and R8 and R9 are -H.
In another embodiment, p and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, p and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.
In another embodiment, p and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CH3.
In another embodiment, p and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CH3, and R9 is -H.
In another embodiment, p and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CF3.
In another embodiment, p and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CF3, and R9 is -H.
In another embodiment, p and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -OCH2CH3.
In another embodiment, p and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -OCH2CH3, and R9 is -H.

In another embodiment, p and m are 0, R, is -CF3, x is 1, A is -C(O)-N(R4)-, is -H, and R8 and R9 are -H.

In another embodiment, p and m are 0, R, is -CF3, x is 1, A is -C(O)-N(R4)-, is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, p and m are 0, R, is -CF3, x is 1, A is -C(O)-N(R4)-, is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.
In another embodiment, p and m are 0, R, is -CF3, x is 1, A is -C(O)-N(R4)-, is -H, R8 is -H, and R9 is -CH3.
In another embodiment, p and in are 0, R, is -CF3, x is 1, A is -C(O)-N(R4)-, is -H, R8 is -CH3, and R9 is -H.
In another embodiment, p and in are 0, R, is -CF3, x is 1, A is -C(O)-N(R4)-, is -H, R8 is -H, and R9 is -CF3.
In another embodiment, p and in are 0, R, is -CF3, x is 1, A is -C(O)-N(R4)-, is -H, R8 is -CF3, and R9 is -H.
In another embodiment, p and in are 0, R, is -CF3, x is 1, A is -C(O)-N(R4)-, is -H, R8 is -H, and R9 is -OCH2CH3.
In another embodiment, p and m are 0, R, is -CF3, x is 1, A is -C(O)-N(R4)-, is -H, R8 is -OCH2CH3, and R9 is -H.
In another embodiment, p and in are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -tert-butyl, and R9 is -H.
In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -tert-butyl, and R9 is -H.
In another embodiment, p and m are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 'S-H, and R9 is -tert-butyl.
In another embodiment, p and in are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R8 is -H, and R9 is -tert-butyl.
In another embodiment, p and in are 0, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -tert-butyl, and R9 is -H.

In another embodiment, p and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -tert-butyl.

In another embodiment, p and in are 0, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CH3, and R9 is -CH3.

In another embodiment, p is 0, m is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R3 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R3 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R3 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1. A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is T. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -halo, and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF31 xis 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -halo, and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R3 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R3 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -CH3, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p and in are 0, R, is -halo, x is 0, R4 is -H, and R8 and R9 are -H.
In another embodiment, p and in are 0, R, is -Cl, x is 0, R4 is -H, and R8 and are -H.

In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R3 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, p and in are 0, R, is -halo, x is 0, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.

In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.

In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -H, and R9 is -CH3.

In another embodiment, p and in are 0, R, is -Cl, x is 0, R4 is -H, R8 is -H, and R9 is -CH3.

In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -CH3, and R9 is -H.

In another embodiment, p and in are 0, R, is -Cl, x is 0, R4 is -H, R8 is -CH3, and R9 is -H.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -H, and R9 is -CF3.
In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -H, and R9 is -CF3.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R3 is -and R9 is -H.
In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -CF31 and R9 is-H.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -H, and R9 is -OCH2CH3.
In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -H, and R9 is -OCH2CH3.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -OCH2CH3, and R9 is -H.
In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -OCH2CH3, and R9 is -H.

In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, and R8 and R9 are -H.
In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.

In another embodiment, p and m are 0, R, is -CH31 x is 0, R4 is -H, R8 is -H, and R9is -CH3.

In another embodiment, p and m are 0, R, is -CH31 x is 0, R4 is -H, R8 is -and R9 is -H.

In another embodiment, p and m are 0, R, is -CH31 x is 0, R4 is -H, R8 is -H, and R9 is -CF3.
In another embodiment, p and m are 0, R, is -CH31 x is 0, R4 is -H, R8 is -and R9 is -H.
In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, R8 is -H, and R9 is -OCH2CH3.
In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, R3 is -OCH2CH3, and R9 is -H.
In another embodiment, p and m are 0, R, is -CF31 x is 0, R4 is -H, and R3 and R9 are -H.

In another embodiment, p and m are 0, R, is -CF3, x is 0, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, p and m are 0, R, is -CF3, x is 0, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.

In another embodiment, p and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -H, and R9 is -CH3.

In another embodiment, p and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -and R9 is -H.

In another embodiment, p and m are 0, R, is -CF31 xis 0, R4 is -H, R8 is -H, and R9 is -CF3.

In another embodiment, p and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -and R9 is -H.

In another embodiment, p and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -H, and R9 is -OCH2CH3.

In another embodiment, p and m are 0, R, is -CF3, x is 0, R4 is -H, R8 is -OCH2CH3, and R9 is -H.

In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -tert-butyl, and R9 is -H.

In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -tert-butyl, and R9 is -H.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -H, and R9 is -tert-butyl.
In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -H, and R9 is -tert-butyl.
In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, R8 is -tert-butyl, and R9 is -H.
In another embodiment, p and m are 0, R, is -CH31 x is 0, R4 is -H, R8 is -H, and R9 is -tert-butyl.
In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, R8 is -CH3, and R9 is -CH3.
In another embodiment, p is 0, m is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -halo, and R9 is -H. In another embodiment, R3 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R3 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -halo, and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R3 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R$ is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R$ is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R$ is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R$ is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, and R$ and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R$ is -halo, and R9 is -H. In another embodiment R$ is -Cl. In another embodiment, R8 is -Br. In one embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R$ is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -CH31 x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -CH3, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrazinyl group, p is 0, m is 1, R, is -CH3 or -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrazinyl group, p is 0, m is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Arl is a pyrazinyl group, p is 0, m is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrazinyl group, p is 0, m is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrazinyl group, p is 0, m is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyridazinyl group, p is 0, m is 1, R, is -CH3 or -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyridazinyl group, p is 0, m is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridazinyl group, p is 0, m is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyridazinyl group, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyridazinyl group, p is 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a thiazanyl group, p is 0, in is 1, R, is -CH3 or -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a thiazanyl group, p is 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a thiazanyl group, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a thiazanyl group, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Arl is a thiazanyl group, p is 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrazinyl group, p is 0, in is 1, R, is -CH3 or -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrazinyl group, p is 0, in is 1, R, is -CH31 x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R$ is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrazinyl group, p is 0, in is 1, R, is -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, Rg is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrazinyl group, p is 0, in is 1, R, is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R$ is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyrazinyl group, p is 0, m is 1, R, is -CH31 x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R3 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Arl is a pyridazinyl group, p is 0, m is 1, R, is -CH3 or -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridazinyl group, p is 0, m is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridazinyl group, p is 0, m is 1, R, is -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridazinyl group, p is 0, m is 1, R, is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a pyridazinyl group, p is 0, m is 1, R, is -CH31 x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a thiazanyl group, p is 0, m is 1, R, is -CH3 or -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a thiazanyl group, p is 0, in is 1, R1 is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a thiazanyl group, p is 0, m is 1, R, is -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a thiazanyl group, p is 0, m is 1, R, is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a thiazanyl group, p is 0, in is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, m is 1 and R3 is -(C,-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzothiazolyl group when x is 0. In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzothiazolyl group when x is 0 and the carbon to which the R3 group is attached is in the R configuration.

In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzothiazolyl group when x is 0. In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzothiazolyl group when x is 0 and the carbon to which the R3 group is attached is in the R
configuration.
In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzothiazolyl group when x is 0. In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzothiazolyl group when x is 0 and the carbon to which the R3 group is attached is in the S configuration.
In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzothiazolyl group when x is 0. In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzothiazolyl group when x is 0 and the carbon to which the R3 group is attached is in the S
configuration.
In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or a thiazanyl group. In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or a thiazanyl group and the carbon to which the R3 group is attached is in the R
configuration.
In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group. In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group and the carbon to which the R3 group is attached is in the R configuration.

In another embodiment, in is 1 and R3is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group. In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group and the carbon to which the R3 group is attached is in the S
configuration.
In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group. In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group and the carbon to which the R3 group is attached is in the S configuration.
The present invention also encompasses compounds of formula (ha):
4.3 The Compounds of Formula (IIa) Nr, (R36 NJ

(Ha) and pharmaceutically acceptable salts thereof, where Arl, R3, R8, R9, RIO and m, are defined above for the Benzoazolylpiperazine Compounds of formula (IIa).
In one embodiment, Arl is a pyridyl group.
In another embodiment, Ar, is a pyrimidinyl group.
In another embodiment, Art is a pyrazinyl group.
In another embodiment, n or p is 0.

In another embodiment, n or p is 1.
In another embodiment, in is 0.
In another embodiment, in is 1.
In another embodiment, R10 is -H.

In another embodiment, RIO is -(C,-C4)alkyl.
In another embodiment, RIO is -CH3.
In another embodiment, R, is -Cl.
In another embodiment, R1 is -Br.
In another embodiment, R, is -I.
In another embodiment, R, is -(C,-C6)alkyl.
In another embodiment, R, is -CH3.
In another embodiment, R, is -NO2.
In another embodiment, R, is -CN.
In another embodiment, R, is -OH.
In another embodiment, R, is -OCH3.
In another embodiment, R, is -NH2.
In another embodiment, R, is -C(halo)3.
In another embodiment, R, is -CH(halo)2.
In another embodiment, R, is -CH2(halo).
In another embodiment, n and p are 1 and R2 is -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, -NH2.
In another embodiment, n and p are 1 and R2 is -(C1-C10)alkyl, -(C2-C10)alkenyl, -(Cz C10)alkynyl, -(C3-C,0)cycloalkyl, -(C8 C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8 C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3-to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups.
In another embodiment, n and p are 1 and R2 is -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
In another embodiment, m is 1 and R3 is -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2.
In another embodiment, m is 1 and R3 is -(C1-C10)alkyl, -(CZ C10)alkenyl, -(CZ
C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C$-C14)tricycloalkyl, -(CS
C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups.
In another embodiment, m is 1 and R3 is -phenyl, -naphthyl, -(C14)aryl or -(5-to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups.
In another embodiment, R8 and R9 are each independently -H, halo, -(C1-C6)alkyl, -O(C1-C6)alkyl, -C(halo)3, -CH(halo)2, or -CH2(halo).

In another embodiment, at least one of R8 or R9 is -H.
In another embodiment, n, p, and m are 0; R1 is -Cl, -Br, or -I; R4 is -H; and and R9 are -H.
In another embodiment, n, p, and m are 0; R1 is -Cl; R4 is -H; and R8 and R9 are -H.
In another embodiment, n, p, and m are 0; R1 is -Cl, -Br, or -I; R4 is -H; R8 is -halo H; and R9 is -H. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br.
In another embodiment, R9 is -F.

In another embodiment, n, p, and m are 0; R1 is -Cl; R4 is -H; R8 is -halo;
and R9 is -H. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br.
In another embodiment, R9 is -F.

In another embodiment, n, p, and m are 0; R1 is -Cl, -Br, or -I; R4 is -H; R8 is -H; and R9 is -CH3. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, n, p, and m are 0; R1 is -Cl; R4 is -H; R8 is -H; and is -CH3. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br.
In another embodiment, R9 is -F.

In another embodiment, n, p, and m are 0; R1 is -Cl, -Br, or -I; R4 is -H; R8 is -CH3; and R9 is -H. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, n, p, and m are 0; R1 is -Cl; R4 is -H; R8 is -CH3; and R9 is -H. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br.
In another embodiment, R9 is -F.

In another embodiment, n, p, and m are 0; R1 is -Cl, -Br, or -I; R4 is -H; R8 is -H; and R9 is -CF3. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, n, p, and m are 0; R, is -Cl; R4 is -H; R8 is -H; and is -CF3. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br.
In another embodiment, R9 is -F.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; R4 is -H; R8 is -CF3; and R9 is -H. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, n, p, and m are 0; R, is -Cl; R4 is -H; R8 is -CF3; and R9 is -H. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br.
In another embodiment, R9 is -F.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; R4 is -H; R8 is -H; and R9 is -OCH2CH3. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, n, p, and m are 0; R, is -Cl; R4 is -H; R8 is -H; and is -OCH2CH3. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; R4 is -H; R8 is -OCH2CH3; and R9 is -H. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, n, p, and m are 0; R, is -Cl; R4 is -H; R8 is -OCH2CH3;
and R9 is -H. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, n, p, and m are 0; R, is -Cl, Br, or -I; R4 is -H; R8 is -H; and R9 is -CH3.
In another embodiment, n, p, and m are 0; R, is -Cl; R4 is -H; R8 is -H; and is -CH3.

In another embodiment, n, p, and m are 0; R, is -Cl, Br, or -I; R4 is -H; R8 is -CH3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl; R4 is -H; R8 is -CH3; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -Cl, Br, or -I; R4 is -H; R8 is -H; and R9 is -CF3.
In another embodiment, n, p, and m are 0; R, is -Cl; R4 is -H; R8 is -H; and is -CF3.
In another embodiment, n, p, and m are 0; R, is -Cl, Br, or -I; R4 is -H; R8 is -CF3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl; R4 is -H; R8 is -CF3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl, Br, or -I; R4 is -H; R8 is -H; and R9 is -OCH2CH3.
In another embodiment, n, p, and m are 0; R, is -Cl; R4 is -H; R8 is -H; and is -OCH2CH3.
In another embodiment, n, p, and m are 0; R, is -Cl, Br, or -I; R4 is -H; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, n, p, and in are 0; R, is -Cl; R4 is -H; R8 is -OCH2CH3;
and R9 is -H.
In another embodiment, n, p, and m are 0, R, is -CH3, R4 is -H, and R8 and R9 are -H.

In another embodiment, n, p, and m are 0; R, is -CH3; R4 is -H; R8 is -H; and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, n, p, and m are 0; R, is -CH3; R4 is -H; R8 is -halo;
and R9 is -H. In another embodiment, R3 is -Cl. In another embodiment, R8 is -Br.
In another embodiment, R8 is -F.
In another embodiment, n, p, and m are 0; R, is -CH3; R4 is -H; R8 is -H; and R9 is -CH3.
In another embodiment, n, p, and m are 0; R, is -CH3; R4 is -H; R3 is -CH3;
and R9 is-H.
In another embodiment, n, p, and m are 0; R, is -CH3; R4 is -H; R8 is -H; and R9 is -CF3.
In another embodiment, n, p, and m are 0; R, is -CH3; R4 is -H; R8 is -CF3;
and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -CH3; R4 is -H; R8 is -H; and R9 is -OCH2CH3.
In another embodiment, n, p, and m are 0; R, is -CH3; R4 is -H; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -CF3; R4 is -H; and R8 and R9 are -H.
In another embodiment, n, p, and m are 0; R, is -CF3; R4 is -H; R8 is -H; and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, n, p, and m are 0; R, is -CF3; R4 is -H; R8 is -halo;
and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br.
In another embodiment, R8 is -F.
In another embodiment, n, p, and m are 0; R, is -CF3; R4 is -H; R8 is -H; and R9 is -CH3.
In another embodiment, n, p, and m are 0; R, is -CF3; R4 is -H; R8 is -CH3;
and R9 is-H.
In another embodiment, n, p, and m are 0; R, is -CF3; R4 is -H; R8 is -H; and R9 is -CF3.
In another embodiment, n, p, and m are 0; R, is -CF3; R4 is -H; R8 is -CF3;
and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -CF3; R4 is -H; R8 is -H; and R9 is -OCH2CH3.
In another embodiment, n, p, and m are 0; R, is -CF3; R4 is -H; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; R4 is -H; R8 is -tert-butyl; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl; R4 is -H; R8 is -tert-butyl;
and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; R4 is -H; R8 is -H; and R9 is -tert-butyl.
In another embodiment, n, p, and m are 0; Rl is -Cl; R4 is -H; R8 is -H; and is -tert-butyl.
In another embodiment, n, p, and m are 0; Rl is -CH3; R4 is -H; R$ is -tert-butyl; and R9 is -H.
In another embodiment, n, p, and m are 0; Rl is -CH3; R4 is -H; R8 is -H; and R9 is -tert-butyl.
In another embodiment, n, p, and m are 0; Rl is -CH3; R4 is -H; R$ is -CH3;
and R9 is -CH3.
In another embodiment, n is 0, Arl is -2-(3-chloropyridyl)-, m is 1, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, the carbon atom to which the R3 group is attached has the R
configuration, R10 is -H, Rg is methyl, and R9 is iso-propyl.
In another embodiment, n is 0, Art is -2-(3-chloropyridyl)-, m is 1, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, the carbon atom to which the R3 group is attached has the R
configuration, R10 is -H, R8 is iso-propyl, and R9 is methyl.
In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; R4 is -H;

is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; and R$ and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; m is 1; Rl is -Cl; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; m is 1; Rl is -Cl, -Br, or -I; R4 is -H;

is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R$ is -H; and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; m is 1; R, is -Cl; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R8 is -H; and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; R4 is -H;

is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R8 is -halo; and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; m is 1; R, is -Cl; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R8 is -halo; and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration. .
In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; R4 is -H;

is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R8 is -H; and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; m is 1; R, is -Cl; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R8 is -H; and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R$ is -CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; in is 1; R, is -C1,;R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R$ is -CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R8 is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R8 is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R3 is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0; in is 1; R, is -Cl; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; Rg is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -benzoimidazole group; R8 is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -benzoimidazole group; R8 is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R8 is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R8 is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH3, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH3, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R8 is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH3, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R8 is -halo, and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R3 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH3, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH3, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH3, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH3, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH3, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH3, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R3 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CF3, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CF3, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CF3, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CF3, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CF3, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, in is 1, R, is -CF3, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, in is 1, R, is -CF3, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, in is 1, R, is -CF3, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, in is 1, R, is -CF3, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R4 is -H; R8 is -tert-butyl; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -Cl, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R4 is -H, R8 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R4 is -H; R8 is -H; and R9 is -tent-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -Cl, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH3, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R4 is -H, R$ is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH3, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R4 is -H, Rg is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R, is -CH3, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R4 is -H, R$ is -CH3, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a pyridyl group; n is 0; m is 1; R, is -CH3, -Cl, -Br, or -I; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group; R4 is -H; R$ is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyridyl group n is 0, m is 1, R, is -CH3, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, R$ is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group; n is 0; m is 1; R, is -Cl, -Br, or -I; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group; R4 is -H; R$ is -H; and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0, m is 1, R, is -Cl, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, R3 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0, m is 1, R, is -CH3, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, Rg is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group; p is 0; m is 1; Rt is -CH3, -Cl, -Br, or -I; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazolyl group; R4 is -H; R3 is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0, m is 1, Rt is -CH3, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazolyl group, R4 is -H, R$ is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group; p is 0; m is 1; R, is -Cl, -Br, or -I; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazolyl group; R4 is -H; R8 is -H; and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0, m is 1, R, is -Cl, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazolyl group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0, m is 1, R, is -CH31 R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazolyl group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrazinyl group; p is 0; m is 1; R, is -CH3, -Cl, -Br, or -I; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazolyl group; R4 is -H; R8 is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrazinyl group, p is 0, m is 1, R, is -CH3, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazolyl group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyrazinyl group; p is 0; m is 1; R, is -Cl, -Br, or -I; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazolyl group; R4 is -H; R8 is -H; and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar1 is a pyrazinyl group, p is 0, m is 1, R1 is -Cl, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazolyl group, R4 is -H, R$ is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Arl is a pyrazinyl group, p is 0, m is 1, R, is -CH3, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazolyl group, R4 is -H, R$ is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, m is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group. In another embodiment, m is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group and the carbon to which the R3 group is attached is in the R configuration.
In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group. In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group and the carbon to which the R3 group is attached is in the R
configuration.
In another embodiment, m is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group. In another embodiment, m is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group and the carbon to which the R3 group is attached is in the S configuration.
In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group. In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- or the benzothiazolyl group and the carbon to which the R3 group is attached is in the S configuration.
In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group, pyrimidinyl group, or pyrazinyl group. In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group, pyrimidinyl group, or pyrazinyl group and the carbon to which the R3 group is attached is in the R
configuration.
In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group, pyrimidinyl group, or pyrazinyl group. In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group, pyrimidinyl group, or pyrazinyl group and the carbon to which the R3 group is attached is in the R configuration.
In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group, pyrimidinyl group, or pyrazinyl group. In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group, pyrimidinyl group, or pyrazinyl group and the carbon to which the R3 group is attached is in the S
configuration.
In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group, pyrimidinyl group, or pyrazinyl group. In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group, pyrimidinyl group, or pyrazinyl group and the carbon to which the R3 group is attached is in the S configuration.

4.4 The Compounds of Formula (IIb) The present invention also encompasses compounds of formula (Ilb):
Ar, Nl (R3)m N

(A)x N `N.R1o (~) and pharmaceutically acceptable salts thereof, where Arl, R3, R8, R9, A. x, and m, are defined above for the Benzoazolylpiperazine Compounds of formula (fib).

In one embodiment, Arl is a pyridazinyl group.
In another embodiment, Arl is a thiazanyl group.
In another embodiment, x is 1 and A is -C(O)-N(R4)-.
In another embodiment, x is 1 and A is -C(S)-N(R4)-.
In another embodiment x is 0.

In another embodiment, x is 1.
In another embodiment p is 0.
In another embodiment, p is 1.
In another embodiment m is 0.
In another embodiment, m is 1.
In another embodiment, R4 is -H.

In another embodiment, R4 is -(Cl-C6)alkyl.
In another embodiment, RIO is -H.
In another embodiment, RIO is -(CI-C4)alkyl.
In another embodiment, RIO is -CH3.
In another embodiment, Art is a pyrazinyl group, x is 1, and A is -C(O)N(R4)-.
In another embodiment, Ax, is a pyrazinyl group, x is 1, and A is -C(S)N(R4)-.
In another embodiment, Art is a thiazanyl group, x is 1, and A is -C(O)N(R4)-.
In another embodiment, Arl is a thiazanyl group, x is 1, and A is -C(S)N(R4)-.
In another embodiment, R1 is -H.

In another embodiment, R1 is -Cl.
In another embodiment, R1 is -Br.
In another embodiment, R1 is -I.

In another embodiment, R1 is -F.
In another embodiment, R1 is -(C1-C6)alkyl.
In another embodiment, R1 is -CH3.
In another embodiment, R1 is -NO2.
In another embodiment, R1 is -CN.
In another embodiment, R1 is -OH.
In another embodiment, R1 is -OCH3.
In another embodiment, R1 is -NH2.

In another embodiment, R1 is -C(halo)3.
In another embodiment, R1 is -CH(halo)2.
In another embodiment, R1 is -CH2(halo).
In another embodiment, p is 1 and R2 is -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, -NH2.
In another embodiment, p is 1 and R2 is -(C1-C10)alkyl, -(C2-C10)alkenyl, -(Cz C10)alkynyl, -(C3-C10)cycloalkyl, -(C$ C14)bicycloalkyl, -(Cg-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(Cg-C14)bicycloalkenyl, -(C8 C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups.
In another embodiment, p is 1 and R2 is -phenyl, -naphthyl, -(C14)aryl, or -(5-to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
In another embodiment, m is 1 and R3 is -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2.

In another embodiment, m is 1 and R3 is -(C1-C10)alkyl, -(C2 C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C3-C14)bicycloalkyl, -(C8 C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(Cg-C14)bicycloalkenyl, -(Cg-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups.
In another embodiment, m is 1 and R3 is -phenyl, -naphthyl, -(C14)aryl or -(5-to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups.
In another embodiment, R8 and R9 are each independently -H, halo, -(C1-C6)alkyl, -O(C1-C6)alkyl, -C(halo)3, -CH(halo)2, or -CH2(halo).
In another embodiment, at least one of R8 or R9 is -H.
In another embodiment, p and m are 0, Rl is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, and R8 and R9 are -H.
In another embodiment, p and m are 0, R1 is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, and R8 and R9 are -H.
In another embodiment, p and m are 0, R1 is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, p and m are 0, R1 is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, p and m are 0, Rl is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.
In another embodiment, p and m are 0, R1 is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.

In another embodiment, p and m are 0, R1 is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CH3.
In another embodiment, p and m are 0, R1 is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CH3.

In another embodiment, p and m are 0, R1 is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CH3, and R9 is -H.
In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3, and R9 is -H.
In another embodiment, p and m are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CF3.

In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CF3.
In another embodiment, p and m are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CF3, and R9 is -H.
In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CF3, and R9 is -H.
In another embodiment, p and m are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -OCH2CH3.

In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -OCH2CH3.
In another embodiment, p and m are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -OCH2CH3, and R9 is -H.

In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -OCH2CH3, and R9 is -H.

In another embodiment, p and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, and R8 and R9 are -H.

In another embodiment, p and m are 0, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, p and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.

In another embodiment, p and m are 0, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CH3.

In another embodiment, p and m are 0, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CH3, and R9 is -H.
In another embodiment, p and in are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -H, and R9 is -CF3.

In another embodiment, p and in are 0, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CF3, and R9 is -H.
In another embodiment, p and in are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -H, and R9 is -OCH2CH3.
In another embodiment, p and in are 0, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -OCH2CH3, and R9 is -H.

In another embodiment, p and in are 0, R, is -CF3, x is 1, A is -C(O)-N(R4)-, R4 is -H, and R8 and R9 are -H.

In another embodiment, p and in are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, p and in are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.

In another embodiment, p and in are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CH3.

In another embodiment, p and in are 0, R, is -CF31 xis 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CH3, and R9 is -H.
In another embodiment, p and in are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CF3.

In another embodiment, p and in are 0, R, is -CF3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CF3, and R9 is -H.

In another embodiment, p and in are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -OCH2CH3.

In another embodiment, p and in are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -OCH2CH3, and R9 is -H.

In another embodiment, p and in are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -tert-butyl, and R9 is -H.
In another embodiment, p and in are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R8 is -tert-butyl, and R9 is -H.

In another embodiment, p and in are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -tert-butyl.

In another embodiment, p and in are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R8 is -H, and R9 is -tert-butyl.

In another embodiment, p and in are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -tert-butyl, and R9 is -H.

In another embodiment, p and in are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -tert-butyl.

In another embodiment, p and in are 0, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3, and R9 is -CH3.

In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -halo, and R9 is -H. In another embodiment, R$ is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -halo, and R9 is -H. In another embodiment, R$ is -Cl. In another embodiment, R$ is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R3 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R$ is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R$ is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R$ is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R3 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R3 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R$ is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, Rl is -CF3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, Rl is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, Rl is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, Rl is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, Rl is -CF31 xis 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CF3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -tent-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH31 xis 1, A is -C(O)-N(R4)-, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R$ is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -CH3, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, and R3 and R9 are -H.
In another embodiment, p and in are 0, R, is -Cl, x is 0, R4 is -H, and R$ and are -H.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.
In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -H, and R9 is -CH3.
In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -H, and R9 is -CH3.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -and R9 is -H.
In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -CH31 and R9 is -H.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -H, and R9 is -CF3.
In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -H, and R9 is -CF3.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -CF3, and R9 is -H.
In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -CF31 and R9 is -H.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -H, and R9 is -OCH2CH3.
In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -H, and R9 is -OCH2CH3.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -OCH2CH3, and R9 is -H.
In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -OCH2CH3, and R9 is -H.
In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, and R8 and R9 are -H.
In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, p and m are 0, R, is -CH31 x is 0, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.
In another embodiment, p and m are 0, R, is -CH31 x is 0, R4 is -H, R8 is -H, and R9 is -CH3.
In another embodiment, p and m are 0, R, is -CH31 x is 0, R4 is -H, R8 is -CH3, and R9 is-H.
In another embodiment, p and m are 0, R, is -CH31 x is 0, R4 is -H, R8 is -H, and R9 is -CF3.
In another embodiment, p and m are 0, R, is -CH31 x is 0, R4 is -H, R8 is -and R9 is -H.
In another embodiment, p and m are 0, R, is -CH3, xis 0, R4 is -H, R8 is -H, and R9 is -OCH2CH3.
In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, R8 is -OCH2CH3, and R9 is -H.
In another embodiment, p and m are 0, R, is -CF31 x is 0, R4 is -H, and R8 and R9 are -H.
In another embodiment, p and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, p and m are 0, R, is -CF3, x is 0, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.
In another embodiment, p and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -H, and R9 is -CH3.
In another embodiment, p and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -CH3, and R9 is -H.
In another embodiment, p and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -H, and R9 is -CF3.
In another embodiment, p and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -CF3, and R9 is -H.
In another embodiment, p and m are 0, R, is -CF3, x is 0, R4 is -H, R8 is -H, and R9 is -OCH2CH3.
In another embodiment, p and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -OCH2CH3, and R9 is -H.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -tert-butyl, and R9 is -H.
In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -tert-butyl, and R9 is -H.

In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -H, and R9 is -tent-butyl.
In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -H, and R9 is -tent-butyl.

In another embodiment, p and m are 0, R, is -CH31 x is 0, R4 is -H, R8 is -tert-butyl, and R9 is -H.

In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, R8 is -H, and R9 is -tert-butyl.

In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, R8 is -and R9 is -CH3.
In another embodiment, p is 0, m is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1. R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R3 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CF3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -CF31 and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF3, xis 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, R8 is -tent-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, R8 is -tent-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, R8 is -H, and R9 is -tent-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, R8 is -tent-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH31 x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -CH31 x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, 5- R4 is -H, R8 is -CH3, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Arl is a pyridazinyl group, p is 0, m is 1, R, is -CH3 or -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Arl is a pyridazinyl group, p is 0, m is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyridazinyl group, p is 0, m is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyridazinyl group, p is 0, m is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyridazinyl group, p is 0, m is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a thiazanyl group, p is 0, m is 1, R, is -CH3 or -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a thiazanyl group, p is 0, m is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R$ is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a thiazanyl group, p is 0, m is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a thiazanyl group, p is 0, m is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R$ is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a thiazanyl group, p is 0, m is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R3 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a pyridazinyl group, p is 0, m is 1, R, is -CH3 or -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, R3 is -H, and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyridazinyl group, p is 0, in is 1, R, is -CH31 x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridazinyl group, p is 0, in is 1, R1 is -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridazinyl group, p is 0, in is 1, R1 is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridazinyl group, p is 0, in is 1, R1 is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a thiazanyl group, p is 0, in is 1, R1 is -CH3 or -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a thiazanyl group, p is 0, in is 1, R1 is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a thiazanyl group, p is 0, in is 1, R, is -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, R$ is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a thiazanyl group, p is 0, in is 1, R, is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, R$ is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a thiazanyl group, p is 0, in is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R4 is -H, R$ is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzoimidazolyl group when x is 0. In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzoimidazolyl group when x is 0 and the carbon to which the R3 group is attached is in the R configuration.

In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzoimidazolyl group when x is 0. In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzoimidazolyl group when x is 0 and the carbon to which the R3 group is attached is in the R configuration.

In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzoimidazolyl group when x is 0. In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzoimidazolyl group when x is 0 and the carbon to which the R3 group is attached is in the S configuration.
In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzoimidazolyl group when x is 0. In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzoimidazolyl group when x is 0 and the carbon to which the R3 group is attached is in the S configuration.
In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridazinyl group or thiazanyl group. In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridazinyl group or thiazanyl group and the carbon to which the R3 group is attached is in the R configuration.
In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyridazinyl group or thiazanyl group. In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyridazinyl group or thiazanyl group and the carbon to which the R3 group is attached is in the R configuration.
In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridazinyl group or thiazanyl group. In = another embodiment, in is 1 and R3 is -(C 1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridazinyl group or thiazanyl group and the carbon to which the R3 group is attached is in the S configuration.

In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyridazinyl group or thiazanyl group. In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyridazinyl group or thiazanyl group and the carbon to which the R3 group is attached is in the S configuration.
4.5 The Compounds of Formula (IIIa) The present invention encompasses compounds of Formula (lRa) Ari (R3)m N

(A)x N: O

(Ma) and pharmaceutically acceptable salts thereof, where Arl, R3, R8, R9, A, x, and m, are defined above for the Benzoazolylpiperazine Compounds of formula (IIIa).
In one embodiment, Arl is a pyridyl group.
In another embodiment, Art is a pyrimidinyl group.
In another embodiment, x is 1 and A is -C(O)-N(R4)-.
In another embodiment, x is 1 and A is -C(S)-N(R4)-.
In another embodiment x is 0.

In another embodiment x is 1.
In another embodiment n or p is 0.
In another embodiment n or p is 1.
In another embodiment m is 0.

In another embodiment m is 1.
In another embodiment, Arl is a pyridyl group, x is 1, and A is -C(O)N(R4)-.
In another embodiment, Arl is a pyridyl group, x is 1, and A is -C(S)N(R4)-.
In another embodiment, Art is a pyrimidinyl group, x is 1, and A is -C(O)N(R4)-.

In another embodiment, Arl is a pyrimidinyl group, x is 1, and A is -C(S)N(R4)-.
In another embodiment, R, is -Cl.
In another embodiment, R, is -Br.
In another embodiment, R, is J.
In another embodiment, R, is -(C1-C6)alkyl.
In another embodiment, R1 is -CH3.
In another embodiment, R1 is -NO2.
In another embodiment, R1 is -CN.
In another embodiment, R1 is -OH.
In another embodiment, R1 is -OCH3.

In another embodiment, R1 is -NH2.
In another embodiment, R1 is -C(halo)3.
In another embodiment, R1 is -CH(halo)2.
In another embodiment, R1 is -CH2(halo).
In another embodiment, n and p are 1 and R2 is -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2.

In another embodiment, n and p are 1 and R2 is -(C1-C10)alkyl, -(C2-C10)alkenyl, -(CZ C10)alkynyl, -(C3 C10)cycloalkyl, -(C8 C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3-to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups.

In another embodiment, n and p are 1 and R2 is -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
In another embodiment, m is 1 and R3 is -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2.

In another embodiment, m is 1 and R3 is -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(CS
C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups.
In another embodiment, m is 1 and R3 is -phenyl, -naphthyl, -(C14)aryl or -(5-to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups.
In another embodiment, R4 is -H.
In another embodiment, R4 is -(C1-C6)alkyl.
In another embodiment, R8 and R9 are each independently -H, halo, -(C1-C6)alkyl, -O(C1-C6)alkyl, -C(halo)3, -CH(halo)2, or -CH2(halo).
In another embodiment, at least one of R8 or R9 is -H.

In another embodiment, n, p, and m are 0; R1 is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; and R8 and R9 are -H.
In another embodiment, n, p, and m are 0; R1 is -Cl; x is 1; A is -C(O)-N(R4)-;
R4 is -H; and R8 and R9 are -H.
In another embodiment, n, p, and m are 0; R1 is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -H; and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, n, p, and m are 0; R1 is -Cl; x is 1; A is -C(O)-N(R4)-;
R4 is -H; R8 is -H; and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, n, p, and m are 0; R1 is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -halo; and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R3 is -Br. In another embodiment, R8 is -F.
In another embodiment, n, p, and m are 0; R1 is -Cl; x is 1; A is -C(O)-N(R4)-;
R4 is -H; R8 is -halo; and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.

In another embodiment, n, p, and m are 0; R1 is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -H; and R9 is -CH3.

In another embodiment, n, p, and m are 0; R1 is -Cl; x is 1; A is -C(O)-N(R4)-;
R4 is -H; R8 is -H; and R9 is -CH3.

In another embodiment, n, p, and m are 0; R1 is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -CH3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl; x is 1; A is -C(O)-N(R4)-;
R4 is -H; R8 is -CH3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H, R8 is -H; and R9 is -CF3.
In another embodiment, n, p, and m are 0; R, is -Cl; x is 1; A is -C(O)-N(R4)-;
R4 is -H; R8 is -H; and R9 is -CF3.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -CF3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl; x is 1; A is -C(O)-N(R4)-;
R4 is -H; R8 is -CF3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -H; and R9 is -OCH2CH3.
In another embodiment, n, p, and m are 0; R, is -Cl; x is 1; A is -C(O)-N(R4)-;
R4 is -H; R8 is -H; and R9 is -OCH2CH3.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl; x is 1; A is -C(O)-N(R4)-;
R4 is -H; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, n, p, and m are 0, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, and R8 and R9 are -H.
In another embodiment, n, p, and m are 0, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, n, p, and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.
In another embodiment, n, p, and m are 0, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CH3.
In another embodiment, n, p, and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CH3, and R9 is -H.
In another embodiment, n, p, and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -H, and R9 is -CF3.
In another embodiment, n, p, and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CF3, and R9 is -H.
In another embodiment, n, p, and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -OCH2CH3.
In another embodiment, n, p, and m are 0, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -OCH2CH3, and R9 is -H.

In another embodiment, n, p, and m are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, and R8 and R9 are -H.

In another embodiment, n, p, and m are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, n, p, and m are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R3 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.
In another embodiment, n, p, and m are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CH3.

In another embodiment, n, p, and m are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CH3, and R9 is -H.

In another embodiment, n, p, and m are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CF3.

In another embodiment, n, p, and m are 0, R, is -CF3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CF3, and R9 is -H.

In another embodiment, n, p, and m are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -OCH2CH3.

In another embodiment, n, p, and m are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -OCH2CH3, and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; R8 is -tent-butyl; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -Cl; x is 1; A is -C(O)-N(R4)-;
R4 is -H; R8 is -tert-butyl; and R9 is -H.
In another embodiment, n, p, and in are 0; R, is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R4 is -H; R$ is -H; and R9 is -tert-butyl.
In another embodiment, n, p, and m are 0; R, is -Cl; x is 1; A is -C(O)-N(R4)-;
R4 is -H; R8 is -H; and R9 is -tert-butyl.
In another embodiment, n, p, and m are 0; R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R$ is -tert-butyl, and R9 is -H.
In another embodiment, n, p, and in are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -tert-butyl.
In another embodiment, n, p, and in are 0, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CH3, and R9 is -CH3.
In another embodiment, n is 0, Art is -2-(3-nitropyridyl)-, m is 0, x is 0, and R$
and R9 are -H.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 1;
A is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; in is 1, R, is -Cl; x is 1, A is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; and R$ and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; x is 1; A
is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R$ is -H; and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl; x is 1; A is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R8 is -H; and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 1;
A is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R3 is -halo; and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0; in is 1; R, is -Cl; x is 1; A is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R8 is -halo; and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 1;
A is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R8 is -H; and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl; x is 1; A is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R8 is -H; and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; x is 1; A
is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R$ is -CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; m is 1; R, is -Cl; x is 1; A is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R$ is -CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; x is 1; A
is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R8 is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; m is 1; R, is -Cl; x is 1; A is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R$ is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; x is 1; A
is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R$ is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; m is 1; R, is -Cl; x is 1; A is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R8 is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; x is 1; A
is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R8 is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl; x is 1; A is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R8 is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 1;
A is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R8 is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; m is 1; R, is -Cl; x is 1; A is -C(O)-N(R4)-; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R8 is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -halo, and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, Rg is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -halo, and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, m is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CF3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R3 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CF3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CF3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 1;
A is -C(O)-N(R4)-; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R4 is -H; R8 is -tert-butyl; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, 'n and p are 0; in is 1; R, is -Cl; x is 1; A is -C(O)-N(R4)-; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R4 is -H; R8 is -tert-butyl; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 1;
A is -C(O)-N(R4)-; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R4 is -H; R8 is -H; and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl; x is 1; A is -C(O)-N(R4)-; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R4 is -H; R8 is -H; and R9 is -tent-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -CH3, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 0; R4 is -H;
and R8 and R9 are -H.

In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; and R8 and R9 are -H.

In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 0; R4 is -H;
R8 is -H; and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, n, p, and in are 0; R, is -Cl; x is 0; R4 is -H; R8 is -H;
and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 0; R4 is -H;
R8 is -halo; and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.

In another embodiment, n, p, and m are 0; R, is -Cl, x is 0; R4 is -H; R8 is -halo; and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.

In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 0; R4 is -H;
R8 is -H; and R9 is -CH3.

In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; R8 is -H;
and R9 is -CH3.

In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 0; R4 is -H;
R8 is -CH3; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; R8 is -CH3; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 0; R4 is -H;
R8 is -H; and R9 is -CF3.

In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; R8 is -H;
and R9 is -CF3.

In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 0; R4 is -H;
R8 is -CF3; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; R8 is -CF3; and R9 is -H.
In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 0; R4 is -H;
R8 is -H; and R9 is -OCH2CH3.
In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; R$ is -H;
and R9 is -OCH2CH3.

In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 0; R4 is -H;
R$ is -OCH2CH3; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; R8 is -OCH2CH3; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -CH31 x is 0; R4 is -H, and R8 and R9 are -H.
In another embodiment, n, p, and m are 0; R, is -CH3, x is 0; R4 is -H, R3 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, n, p, and m are 0; R, is -CH3, x is 0; R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R$ is -Br. In another embodiment, R8 is -F.

In another embodiment, n, p, and m are 0; R, is -CH31 x is 0; R4 is -H, R8 is -H, and R9 is -CH3.

In another embodiment, n, p, and m are 0, R, is -CH31 x is 0, R4 is -H, R8 is -CH3, and R9 is -H.

In another embodiment, n, p, and m are 0, R, is -CH3, x is 0, R4 is -H, R3 is -H, and R9 is -CF3.

In another embodiment, n, p, and m are 0, R, is -CH31 x is 0, R4 is -H, R8 is -CF3, and R9 is -H.

In another embodiment, n, p, and m are 0, R, is -CH3, x is 0, R4 is -H, R3 is -H, and R9 is -OCH2CH3.

In another embodiment, n, p, and m are 0, R, is -CH31 x is 0, R4 is -H, R$ is -OCH2CH3, and R9 is -H.

In another embodiment, n, p, and m are 0, R, is -CF31 x is 0, R4 is -H, and R$
and R9 are -H.
In another embodiment, n, p, and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, n, p, and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.

In another embodiment, n, p, and m are 0, R, is -CF3, x is 0, R4 is -H, R8 is -H, and R9 is -CH3.

In another embodiment, n, p, and m are 0, R, is -CF3, x is 0, R4 is -H, R8 is -CH3, and R9 is -H.

In another embodiment, n, p, and m are 0. R, is -CF3, x is 0, R4 is -H, R8 is -H, and R9 is -CF3.

In another embodiment, n, p, and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -CF3, and R9 is -H.

In another embodiment, n, p, and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -H, and R9 is -OCH2CH3.

In another embodiment, n, p, and m are 0, R, is -CF3, x is 0, R4 is -H, R8 is -OCH2CH3, and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 0; R4 is -H;
R8 is -tert-butyl; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; R8 is -tert-butyl; and R9 is -H.

In another embodiment, n, p, and m are 0; R, is -Cl, -Br, or -I; x is 0; R4 is -H;
R8 is -H; and R9 is -tert-butyl.

In another embodiment, n, p, and m are 0; R, is -Cl; x is 0; R4 is -H; R8 is -H;
and R9 is -tert-butyl.

In another embodiment, n, p, and m are 0, R, is -CH3, x is 0, R4 is -H, R8 is -tert-butyl, and R9 is -H.

In another embodiment, n, p, and m are 0, R, is -CH3, x is 0, R4 is -H, R8 is -H, and R9 is -tert-butyl.

In another embodiment, n, p, and m are 0, R, is -CH31 x is 0, R4 is -H, R8 is -CH31 and R9 is -CH3.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 0;
R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0; in is 1, R, is -Cl; x is 0; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 0;
R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R8 is -H; and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0; in is 1; R, is -Cl; x is 0; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R8 is -H; and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 0;
R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R8 is -halo; and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0; in is 1, R, is -Cl; x is 0; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R3 is -halo; and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R$ is -Br. In another embodiment, R3 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; x is 0;
R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R8 is -H; and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0; in is 1, R, is -Cl; x is 0; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R$ is -H; and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 0;
R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0; in is 1; R, is -Cl; x is 0; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R$ is -CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p 0; in is 1; R, is -Cl, -Br, or -I; x is 0; R4 is -H;
R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R$ is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p 0; m is 1; R, is -Cl; x is 0; R4 is -H; R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R8 is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; x is 0;
R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R8 is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R, is -Cl; x is 0; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R8 is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; x is 0;
R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R8 is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; m is 1; R, is -Cl; x is 0; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R8 is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R, is -Cl, -Br, or -I; x is 0;
R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R8 is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R, is -Cl; x is 0; R4 is -H; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R8 is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R, is -CH31 x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, and R3 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R, is -CH31 x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -halo, and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, n and p are 0, m is 1, R, is -CH31 x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CH3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH31 x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -CF3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, m is 1, R, is -CF3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R3 is -halo, and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, in is 1, R, is -CF3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R, is -CF3, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R, is -CF31 x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R$ is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 0;
R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R4 is -H, Rg is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl; x is 0; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group;
R4 is -H; R8 is -tert-butyl; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl, -Br, or -I; x is 0;
R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R4 is -H; R$ is -H; and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, n and p are 0; in is 1; R, is -Cl; x is 0; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group;
R4 is -H; R$ is -H; and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R3 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R$ is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, n and p are 0, in is 1, R, is -CH31 x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R3 is -CH3, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group; n is 0; in is 1; R, is -CH3, -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R4 is -H; R$ is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R

configuration.
In another embodiment, Ar, is a pyridyl group, n is 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R3 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration.

In another embodiment, Ar, is a pyridyl group; n is 0; in is 1; R, is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R4 is -H; R8 is -H; and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration.
In another embodiment, Ar, is a pyridyl group, n is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R$ is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration.

In another embodiment, Art is a pyridyl group, n is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration.
In another embodiment, Arl is a pyrimidinyl group; p is 0; m is 1; R, is -CH3, -Cl, -Br, -I; x is 1; A is -C(O)-N(R4)-; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R4 is -H; R8 is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R

configuration.
In another embodiment, Arl is a pyrimidinyl group, p is 0, m is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration.
In another embodiment, Art is a pyrimidinyl group; p is 0; m is 1; R, is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R4)-; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group; R4 is -H; R8 is -H; and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration.

In another embodiment, Ar, is a pyrimidinyl group, p is 0, m is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration.

In another embodiment, Ar, is a pyrimidinyl group, p is 0, m is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration.
In another embodiment, Art is a pyridyl group; n is 0; m is 1; R, is -CH3, -Cl, -Br, or -I; x is 0; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R4 is -H; R8 is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration.

In another embodiment, Ar, is a pyridyl group, n is 0, m is 1, R, is -CH31 x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration.
In another embodiment, Ar, is a pyridyl group; n is 0; m is 1; R, is -Cl, -Br, or -I; x is 0; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R4 is -H; R8 is -H; and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration.
In another embodiment, Art is a pyridyl group, n is 0, in is 1, R, is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration.
In another embodiment, Art is a pyridyl group, n is 0, m is 1, R, is -CH31 x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration.

In another embodiment, Arl is a pyrimidinyl group; p is 0; in is 1; R, is -CH3, -Cl, -Br, or -I; x is 0; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R4 is -H; R8 is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0, in is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration.

In another embodiment, Art is a pyrimidinyl group; p is 0; in is 1; R, is -Cl, -Br, or -I; x is 0; R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R4 is -H; R8 is -H; and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration.
In another embodiment, Ar, is a pyrimidinyl group, p is 0, m is 1, R, is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration.

In another embodiment, Ar, is a pyrimidinyl group, p is 0, m is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration.
In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- or the benzooxazolyl group. In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- or the benzooxazolyl group and the carbon to which the R3 group is attached is in the R configuration.
In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- or the benzooxazolyl group. In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- or the benzooxazolyl group and the carbon to which the R3 group is attached is in the R configuration.
In another embodiment, in is 1 and R3 is -(CI-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- or the benzooxazolyl group. In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- or the benzooxazolyl group and the carbon to which the R3 group is attached is in the S configuration.
In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- or the benzooxazolyl group. In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- or the benzooxazolyl group and the carbon to which the R3 group is attached is in the S configuration.
In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group. In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group and the carbon to which the R3 group is attached is in the R configuration.

In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group. In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group and the carbon to which the R3 group is attached is in the R configuration.
In another embodiment, m is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group. In another embodiment, m is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group and the carbon to which the R3 group is attached is in the S configuration.
In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group. In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group and the carbon to which the R3 group is attached is in the S configuration.

4.6 The Compounds of Formula (IIIb) The present invention also encompasses compounds of formula (IIIb):
Ari J (R3)m N

(A)x Ni`
O

(IIlb) and pharmaceutically acceptable salts thereof, where Art, R3, R8, R9, A, x, and m, are defined above for the Benzoazolylpiperazine Compounds of formula (IIIb).
In one embodiment, Art is a pyrazinyl group.
In another embodiment, Art is a pyridazinyl group.
In another embodiment, Art is a thiazanyl group.
In another embodiment, x is 1 and A is -C(O)-N(R4)-.
In another embodiment, x is 1 and A is -C(S)-N(R4)-.
In another embodiment x is 0.
In another embodiment, x is 1.
In another embodiment, p is 0.
In another embodiment, p is 1.
In another embodiment, m is 0.
In another embodiment, m is 1.

In another embodiment, Ar, is a pyrazinyl group, x is 1, and A is -C(O)N(R4)-.
In another embodiment, Ar, is a pyrazinyl group, x is 1, and A is -C(S)N(R4)-.
In another embodiment, Ar, is a pyridazinyl group, x is 1, and A is -C(O)N(R4)-.
In another embodiment, Ar, is a pyridazinyl group, x is 1, and A is -C(S)N(R4)-.

In another embodiment, Art is a thiazanyl group, x is 1, and A is -C(O)N(R4)-.
In another embodiment, Ar, is a thiazanyl group, x is 1, and A is -C(S)N(R4)-.
In another embodiment, R, is -H.
In another embodiment, R, is -Cl.
In another embodiment, R, is -Br.
In another embodiment, R, is -I.
In another embodiment, R, is -F.

In another embodiment, R, is -(C,-C6)alkyl.
In another embodiment, R, is -CH3.
In another embodiment, R, is -NO2.
In another embodiment, R, is -CN.
In another embodiment, R, is -OH.
In another embodiment, R, is -OCH3.
In another embodiment, R, is -NH2.
In another embodiment, R, is -C(halo)3.
In another embodiment, R, is -CH(halo)2.
In another embodiment, R, is -CH2(halo).

In another embodiment, p is 1 and R2 is -halo, -CN, -OH, -O(C,-C6)alkyl, -NO2, -NH2.
In another embodiment, p is 1 and R2 is -(C1-C10)alkyl, -(Ci C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C3-C14)bicycloalkyl, -(Cs-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C$-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups.
In another embodiment, p is 1 and R2 is -phenyl, -naphthyl, -(C14)aryl, or -(5-to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
In another embodiment, m is 1 and R3 is -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2.
In another embodiment, m is 1 and R3 is -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C$ C14)bicycloalkyl, -(C$
C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C$ C14)bicycloalkenyl, -(C8 C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups.

In another embodiment, m is 1 and R3 is -phenyl, -naphthyl, -(C14)aryl or -(5-to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups.
In another embodiment, R4 is -H.
In another embodiment, R4 is -(C1-C6)alkyl.
In another embodiment, R8 and R9 are each independently -H, halo, -(C1-C6)alkyl, -O(C1-C6)alkyl, -C(halo)3, -CH(halo)2, or -CH2(halo).

In another embodiment, at least one of R8 or R9 is -H.
In another embodiment, p and m are 0, Rl is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, and R$ and R9 are -H.

In another embodiment, p and m are 0, R1 is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, and R$ and R9 are -H.

In another embodiment, p and m are 0, R1 is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R$ is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, p and m are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is T.
In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is T.

In another embodiment, p and m are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CH3.

In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CH3.
In another embodiment, p and m are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CH3, and R9 is -H.

In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CH3, and R9 is -H.

In another embodiment, p and m are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CF3.

In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CF3.

In another embodiment, p and m are 0. R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CF3, and R9 is -H.

In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CF3, and R9 is -H.

In another embodiment, p and m are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -OCH2CH3.

In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R.9 is -OCH2CH3.

In another embodiment, p and m are 0. R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -OCH2CH3, and R9 is -H.
In another embodiment, p and m are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -OCH2CH3, and R9 is -H.

In another embodiment, p and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, and R8 and R9 are -H.

In another embodiment, p and m are 0, R, is -CH3, xis 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, p and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.

In another embodiment, p and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CH3.

In another embodiment, p and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CH3, and R9 is -H.
In another embodiment, p and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CF3.

In another embodiment, p and m are 0, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CF3, and R9 is -H.

In another embodiment, p and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -OCH2CH3.
In another embodiment, p and m are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -OCH2CH3, and R9 is -H.

In another embodiment, p and m are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, and R8 and R9 are -H.
In another embodiment, p and m are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is T.
In another embodiment, p and m are 0, R, is -CF3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is T.
In another embodiment, p and m are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CH3.

In another embodiment, p and in are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CH3, and R9 is -H.

In another embodiment, p and in are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -CF3.

In another embodiment, p and in are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CF3, and R9 is -H.

In another embodiment, p and m are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -OCH2CH3.
In another embodiment, p and in are 0, R, is -CF31 x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -OCH2CH3, and R9 is -H.
In another embodiment, p and in are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -tert-butyl, and R9 is -H.

In another embodiment, p and in are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R8 is -tert-butyl, and R9 is -H.

In another embodiment, p and in are 0, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 'S-H, and R9 is -tert-butyl.

In another embodiment, p and in are 0, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R8 is -H, and R9 is -tert-butyl.

In another embodiment, p and in are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -tert-butyl, and R9 is -H.

In another embodiment, p and in are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -H, and R9 is -tert-butyl.

In another embodiment, p and in are 0, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R4 is -H, R8 is -CH3, and R9 is -CH3.

In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, and R3 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -halo, and R9 is -H. In another embodiment, R3 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, m is 1. R, is -halo, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R$ is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R$ is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R$ is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CF31 and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH3a x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, and Rg and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -halo, and R9 is -H. In another embodiment R$ is -Cl. In another embodiment, R3 is -Br. In another embodiment, R$ is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R3 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R3 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF3, x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -halo, and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CF31 xis 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CF31 x is 1, A is -C(O)-N(R4)-, is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is halo, x is 1, A is -C(O)-N(R4)-, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R3 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -CH3, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, and R8 and R9 are -H.
In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, and R8 and are -H.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.
In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -H, and R9 is -CH3.

In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -H, and R9is -CH3.

In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -CH3, and R9 is -H.

In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -CH31 and R9 is -H.
In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -H, and Rg is -CF3.

In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -H, and Rg is -CF3.

In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -CF3, and Rg is -H.

In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -CF31 and Rg is -H.

In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -H, and Rg is -OCH2CH3.

In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -H, and Rg is -OCH2CH3.

In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -OCH2CH3, and Rg is -H.

In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -OCH2CH3, and Rg is -H.

In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, and R8 and Rg are -H.

In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, R8 is -H, and Rg is -halo. In another embodiment, Rg is -Cl. In another embodiment, Rg is -Br. In another embodiment, Rg is -F.

In another embodiment, p and m are 0, R, is -CH31 x is 0, R4 is -H, R8 is -halo, and Rg is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.

In another embodiment, p and m are 0, R, is -CH31 x is 0, R4 is -H, R8 is -H, and Rg is -CH3.

In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, R8 is -CH3, and Rg is -H.

In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, R8 is -H, and Rg is -CF3.
In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, R3 is -CF3, and R9 is -H.
In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, R8 is -H, and R9 is -OCH2CH3.

In another embodiment, p and m are 0, R, is -CH3, x is 0, R4 is -H, R8 is -OCH2CH3, and R9 is -H.

In another embodiment, p and m are 0, R, is -CF31 x is 0, R4 is -H, and R8 and R9 are -H.
In another embodiment, p and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F.

In another embodiment, p and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F.

In another embodiment, p and m are 0, R, is -CF3, x is 0, R4 is -H, R8 is -H, and R9 is-CH3.

In another embodiment, p and m are 0, R, is -CF3, x is 0, R4 is -H, R8 is -and R9 is -H.

In another embodiment, p and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -H, and R9 is -CF3.

In another embodiment, p and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -CF3, and R9 is -H.

In another embodiment, p and m are 0, R, is -CF31 x is 0, R4 is -H, R8 is -H, and R9 is -OCH2CH3.

In another embodiment, p and m are 0, R, is -CF3, x is 0, R4 is -H, R8 is -OCH2CH3, and R9 is -H.

In another embodiment, p and m are 0, R, is -halo, x is 0, R4 is -H, R8 is -tert-butyl, and R9 is -H.

In another embodiment, p and m are 0, R, is -Cl, x is 0, R4 is -H, R8 is -tert-butyl, and R9 is -H.
In another embodiment, p and in are 0, R, is -halo, x is 0, R4 is -H, R8 is -H, and R9 is -tert-butyl.
In another embodiment, p and in are 0, R, is -Cl, x is 0, R4 is -H, R$ is -H, and R9 is -tert-butyl.
In another embodiment, p and in are 0, R, is -CH31 x is 0, R4 is -H, R$ is -tert-butyl, and R9 is -H.
In another embodiment, p and in are 0, R, is -CH3, x is 0, R4 is -H, R8 is -H, and R9 is -tert-butyl.
In another embodiment, p and in are 0, R, is -CH31 x is 0, R4 is -H, R3 is -CH3, and R9 is -CH3.
In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, and R3 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, and R$ and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R$ is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R$ is -H, and R9 is -halo. In another embodiment, R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -halo, and R9 is -H. In another embodiment, R8 is -Cl. In another embodiment, R8 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 0. R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R3 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -halo, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R4 is -H, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R$ is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, and R$ and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R$ is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -halo, and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R3 is -Br. In another embodiment, R8 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, and R$ and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1. R, is -CF31 xis 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R$ is -H, and R9 is -halo. In another embodiment R9 is -Cl. In another embodiment, R9 is -Br. In another embodiment, R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -halo, and R9 is -H. In another embodiment R8 is -Cl. In another embodiment, R$ is -Br. In another embodiment, R3 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, m is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R3 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF31 x is 0, R4 is -H. R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R$ is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, in is 1, R, is -CF3, x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -H, and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -CF3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -H, and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R, is -CF31 x is 0, R4 is -H, R3 is -and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R8 is -OCH2CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R, is -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R, is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -tent-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R, is -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration In another embodiment, p is 0, in is 1, R, is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -tert-butyl, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, Rt is -CH31 x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, p is 0, in is 1, Rt is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -CH3, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrazinyl group, p is 0, in is 1, R, is -CH3 or -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrazinyl group, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrazinyl group, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyrazinyl group, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyrazinyl group, p is 0, in is 1, R, is -CH31 x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is T. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a pyridazinyl group, p is 0, in is 1, R, is -CH3 or -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyridazinyl group, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a pyridazinyl group, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyridazinyl group, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridazinyl group, p is 0, m is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R3 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a thiazanyl group, p is 0, in is 1, R, is -CH3 or -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a thiazanyl group, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R$ is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a thiazanyl group, p is 0, in is 1, R, is -halo, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a thiazanyl group, p is 0, in is 1, R, is -Cl, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R$ is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a thiazanyl group, p is 0, in is 1, R, is -CH3, x is 1, A is -C(O)-N(R4)-, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyrazinyl group, p is 0, in is 1, R, is -CH3 or -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyrazinyl group, p is 0, in is 1, R, is -CH31 x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyrazinyl group, p is 0, in is 1, R, is -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a pyrazinyl group, p is 0, in is 1, R, is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyrazinyl group, p is 0, in is 1, R, is -CH31 x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridazinyl group, p is 0, in is 1, R, is -CH3 or -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyridazinyl group, p is 0, in is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R$ is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridazinyl group, p is 0, m is 1, R, is -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridazinyl group, p is 0, in is 1, R, is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, Rg is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyridazinyl group, p is 0, in is 1, R, is -CH31 x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R$ is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a thiazanyl group, p is 0, in is 1, R, is -CH3 or -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a thiazanyl group, p is 0, m is 1, R, is -CH31 x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -Cl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a thiazanyl group, p is 0, m is 1, R, is -halo, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R3 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a thiazanyl group, p is 0, in is 1, R, is -Cl, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -Br. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a thiazanyl group, p is 0, m is 1, R, is -CH3, x is 0, R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R4 is -H, R8 is -H, and R9 is -F. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, m is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzooxazolyl group when x is 0. In another embodiment, in is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzooxazolyl group when x is 0 and the carbon to which the R3 group is attached is in the R configuration.
In another embodiment, in is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzooxazolyl group when x is 0. In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzooxazolyl group when x is 0 and the carbon to which the R3 group is attached is in the R
configuration.
In another embodiment, m is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzooxazolyl group when x is 0. In another embodiment, m is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzooxazolyl group when x is 0 and the carbon to which the R3 group is attached is in the S configuration.
In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzooxazolyl group when x is 0. In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R4)- when x is 1 or the benzooxazolyl group when x is 0 and the carbon to which the R3 group is attached is in the S
configuration.
In another embodiment, m is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group. In another embodiment, m is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group and the carbon to which the R3 group is attached is in the R
configuration.
In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group. In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group and the carbon to which the R3 group is attached is in the R configuration.
In another embodiment, m is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group. In another embodiment, m is 1 and R3 is -(C1-C4)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group and the carbon to which the R3 group is attached is in the S
configuration.
In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group. In another embodiment, m is 1 and R3 is -CH3 and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group and the carbon to which the R3 group is attached is in the S configuration.
4.7 The Compounds of Formula (IVa) The present invention also encompasses compounds of formula (IVa):
Ar, ~O
HN
Are (IVa) and pharmaceutically acceptable salts thereof, where Arl, Ar2, and R3, are defined above for the Benzoazolylpiperazine Compounds of formula (Na).

In one embodiment, Ar1 is a pyridyl group.

In another embodiment, Art is a pyrimidinyl group.
In another embodiment, Ar2 is a benzothiazolyl group.
In another embodiment, Are is a benzooxazolyl group.
In another embodiment, Are is a benzoimidazolyl group.
In another embodiment, n or p is 0.

In another embodiment, n or p is 1.
In another embodiment, R1 is -Cl.
In another embodiment, R1 is -Br.
In another embodiment, R, is -I.
In another embodiment, R, is -F.
In another embodiment, R, is -(C1-C6)alkyl.
In another embodiment, R1 is -CH3.
In another embodiment, R1 is -NO2.

In another embodiment, R1 is -CN.
In another embodiment, R1 is -OH.
In another embodiment, R, is -OCH3.

In another embodiment, R, is -NH2.
In another embodiment, R, is -C(halo)3.
In another embodiment, R, is -CH(halo)2.
In another embodiment, R, is -CH2(halo).
In another embodiment, n and p are 1 and R2 is -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2.
In another embodiment, n and p are 1 and R2 is -(C1-C10)alkyl, -(CZ
C10)alkenyl, -(CZ C10)a]kynyl, -(C3-C10)cycloalkyl, -(C$ C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C$ C14)bicycloalkenyl, -(C$
C14)tricycloalkenyl, -(3-to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups.
In another embodiment, n and p are 1 and R2 is -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
In another embodiment, R3 is -H.
In another embodiment, R3 is -CH3.
In another embodiment, R8 and R9 are each independently -H, halo, -(C1-C6)alkyl, -O(C1-C6)alkyl, -C(halo)3, -CH(halo)2, or -CH2(halo).
In another embodiment, at least one of R8 and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or, -I; ; Ar2 is a benzothiazolyl group; and R8 and R9 are -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F; Ar2 is a benzothiazolyl group; and R8 and R9 are -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Ar2 is a benzothiazolyl group; R8 is -H; and R9 is -halo.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, Ar2 is a benzothiazolyl group; R8 is -H; and R9 is -chloro.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; Rt is -F, Ar2 is a benzothiazolyl group; R8 is -H; and R9 is -bromo.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, Ar2 is a benzothiazolyl group; R8 is -H; and R9 is -fluoro.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, Ar2 is a benzothiazolyl group; R8 is -H; and R9 is -iodo.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -halo; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -chloro; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -bromo; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Ar2 is a benzothiazolyl group; R8 is -fluoro; and R9 is -H.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -iodo; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F; Ar2 is a benzothiazolyl group; R8 is -halo, and R9 is -H.
In'another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F; Ar2 is a benzothiazolyl group; R8 is -chloro, and R9 is -H.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F; Are is a benzothiazolyl group; R8 is -bromo, and R9 is -H.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F; Ar2 is a benzothiazolyl group; R8 is -fluoro, and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F; Are is a benzothiazolyl group; R8 is -iodo, and R9 is -H.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; ; Are is a benzothiazolyl group; R8 is -H; and R9 is -CH3.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F; Ar2 is a benzothiazolyl group; R8 is -H, and R9 is -CH3.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -CH3; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F; Ar2 is a benzothiazolyl group; R8 is -CH3, and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -H; and R9 is -CF3.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F; Ar2 is a benzothiazolyl group; R$ is -H; and R9 is -CF3.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -CF3; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F; Are is a benzothiazolyl group; R8 is -CF3; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -H; and R9 is -OCH2CH3.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -H; R, is -F; Ar2 is a benzothiazolyl group; R8 is -H; and R9 is -OCH2CH3.
In another embodiment Art is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, Art Art is a pyridyl group, n is 0; R3 is -H; R, is -F;
Ar2 is a benzothiazolyl group; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -tert-butyl; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F; Ar2 is a benzothiazolyl group; R8 is -tert-butyl; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -H; and R9 is -tert-butyl.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is R, is -F;
Are is a benzothiazolyl group; R8 is -H; and R9 is -tert-butyl.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or, -I; Are is a benzothiazolyl group; and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzothiazolyl group; and R$ and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Ar2 is a benzothiazolyl group; R8 is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F, Are is a benzothiazolyl group; R8 is -H; and R9 is -chloro. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F, Ar2 is a benzothiazolyl group; R8 is -H; and R9 is -bromo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F, Ar2 is a benzothiazolyl group; R3 is -H; and R9 is -fluoro. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F, Ar2 is a benzothiazolyl group; R8 is -H; and R9 is -iodo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R$ is -halo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R1 is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -chloro; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R1 is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -bromo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R1 is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -fluoro; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R1 is -F, -Cl, -Br, or -I; Ara is a benzothiazolyl group; R8 is -iodo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R1 is -F;
Ar2 is a benzothiazolyl group; R8 is -halo, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R1 is -F;
Ar2 is a benzothiazolyl group; R8 is -chloro, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R1 is -F;
Ar2 is a benzothiazolyl group; R8 is -bromo, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R1 is -F;
Ar2 is a benzothiazolyl group; R8 is -fluoro, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzothiazolyl group; R8 is -iodo, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; ; Are is a benzothiazolyl group; R$ is -H; and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzothiazolyl group; R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzothiazolyl group; R$ is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R$ is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzothiazolyl group; R$ is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzothiazolyl group; R8 is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzothiazolyl group; R8 is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzothiazolyl group; R8 is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Ar2 is a benzothiazolyl group; R8 is -tert-butyl; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F;

is -tert-butyl; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -H; and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is R, is -F; Are is a benzothiazolyl group; R8 is -H; and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or, -I; ; Ar2 is a benzothiazolyl group; and R8 and R9 are -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzothiazolyl group; and R8 and R9 are -H.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -H; and R9 is -halo.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, Are is a benzothiazolyl group; R8 is -H; and R9 is -chloro.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, Are is a benzothiazolyl group; R8 is -H; and R9 is -bromo.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, Are is a benzothiazolyl group; R8 is -H; and R9 is -fluoro.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, Are is a benzothiazolyl group; R8 is -H; and R9 is -iodo.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -halo; and R9 is -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Ar2 is a benzothiazolyl group; R8 is -chloro; and R9 is -H.
In another embodiment, Arl is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Ar2 is a benzothiazolyl group; R3 is -bromo; and R9 is -H.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R3 is -fluoro; and R9 is -H.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -iodo; and R9 is -H.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Ar2 is a benzothiazolyl group; R8 is -halo, and R9 is -H.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzothiazolyl group; R8 is -chloro, and R9 is -H.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzothiazolyl group; R8 is -bromo, and R9 is -H.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzothiazolyl group; R8 is -fluoro, and R9 is -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzothiazolyl group; R8 is -iodo, and R9 is -H.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; ; Are is a benzothiazolyl group; R8 is -H; and R9 is -CH3.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Ar2 is a benzothiazolyl group; R8 is -H, and R9 is -CH3.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -CH3; and R9 is -H.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzothiazolyl group; R8 is -CH3, and R9 is -H.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -H; and R9 is -CF3.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Ar2 is a benzothiazolyl group; R8 is -H; and R9 is -CF3.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -CF3; and R9 is -H.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzothiazolyl group; R8 is -CF3; and R9 is -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -H; and R9 is -OCH2CH3.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzothiazolyl group; R8 is -H; and R9 is -OCH2CH3.

In another embodiment Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -OCH2CH3; and R9 is -H.

In another embodiment, Art Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F; Are is a benzothiazolyl group; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -tert-butyl; and R9 is -H.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzothiazolyl group; R8 is -tert-butyl; and R9 is -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -H; and R9 is -tert-butyl.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is R, is -F; Are is a benzothiazolyl group; R3 is -H; and R9 is -tert-butyl.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or, -I; ; Are is a benzothiazolyl group; and R3 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Ar2 is a benzothiazolyl group; and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Arl is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, Are is a benzothiazolyl group; R3 is -H; and R9 is -chloro. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, Are is a benzothiazolyl group; R8 is -H; and R9 is -bromo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, Are is a benzothiazolyl group; R3 is -H; and R9 is -fluoro. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, Are is a benzothiazolyl group; R8 is -H; and R9 is -iodo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -halo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -chloro; and R9 is -H.
In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -bromo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -fluoro; and R9 is -H.
In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -iodo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzothiazolyl group; R$ is -halo, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Ar2 is a benzothiazolyl group; R$ is -chloro, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzothiazolyl group; R8 is -bromo, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzothiazolyl group; R8 is -fluoro, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzothiazolyl group; R8 is -iodo, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Arl is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; ; Are is a benzothiazolyl group; R8 is -H; and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzothiazolyl group; R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R8 is -CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Ara is a benzothiazolyl group; R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Ara is a benzothiazolyl group; R8 is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F.
Are is a benzothiazolyl group; R8 is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Ar2 is a benzothiazolyl group; R8 is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Arl is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzothiazolyl group; R$ is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; Rg is -H; and R9 is -OCH2CH3.
In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzothiazolyl group; R3 is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Ar2 is a benzothiazolyl group; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzothiazolyl group; R$ is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzothiazolyl group; R$ is -tert-butyl; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S

configuration.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
R8 is -tent-butyl; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is R, is -F, -Cl, -Br, or -I; Ara is a benzothiazolyl group; R8 is -H; and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S

configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is R, is -F; Are is a benzothiazolyl group; R8 is -H; and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or, -I; ; Ara is a benzoimidazolyl group; and R8 and R9 are -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F; Ar2 is a benzoimidazolyl group; and R8 and R9 are -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -H; and R9 is -halo.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F, Ar2 is a benzoimidazolyl group; R8 is -H; and R9 is -chloro.

In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -H; R, is -F, Ar2 is a benzoimidazolyl group; R8 is -H; and R9 is -bromo.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F, Ara is a benzoimidazolyl group; R8 is -H; and R9 is -fluoro.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -H; R, is -F, Ar2 is a benzoimidazolyl group; R8 is -H; and R9 is -iodo.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -halo; and R9 is -H.

In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -chloro; and R9 is -H.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -bromo; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R3 is -fluoro; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -iodo; and R9 is -H.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -H; R, is -F; Are is a benzoimidazolyl group; R8 is -halo, and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F; Are is a benzoimidazolyl group; R8 is -chloro, and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F; Ar2 is a benzoimidazolyl group; R8 is -bromo, and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F; Ar2 is a benzoimidazolyl group; R8 is -fluoro, and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F; Ar2 is a benzoimidazolyl group; R8 is -iodo, and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; ; Are is a benzoimidazolyl group; R8 is -H; and R9 is -CH3.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F; Ar2 is a benzoimidazolyl group; R8 is -H, and R9 is -CH3.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -CH3; and R9 is -H.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F; Ar2 is a benzoimidazolyl group; R8 is -CH3, and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -H; and R9 is -CF3.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F; Ar2 is a benzoimidazolyl group; R8 is -H; and R9 is -CF3.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -CF3; and R9 is -H.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -H; R, is -F; Are is a benzoimidazolyl group; R8 is -CF3; and R9 is -H.
In another embodiment, Ar1 is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -H; and R9 is -OCH2CH3.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F; Ar2 is a benzoimidazolyl group; R8 is -H; and R9 is -OCH2CH3.
In another embodiment Ar, is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, Ar, Ar1 is a pyridyl group, n is 0; R3 is -H; R, is -F;
Are is a benzoimidazolyl group; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -tert-butyl; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F; Ar2 is a benzoimidazolyl group; R8 is -tent-butyl; and R9 is -H.
' In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is R1 is -F, -Cl, -Br, or -I; Ar2 is a benzoimidazolyl group; R8 is -H; and R9 is -tert-butyl.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is R1 is -F;
Are is a benzoimidazolyl group; R8 is -H; and R9 is -tert-butyl.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R1 is -F, -Cl, -Br, or, -I; ; Are is a benzoimidazolyl group; and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R1 is -F;
Ar2 is a benzoimidazolyl group; and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R1 is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F, Ar2 is a benzoimidazolyl group; R$ is -H; and R9 is -chloro. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F, Ar2 is a benzoimidazolyl group; R$ is -H; and R9 is -bromo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F, Ar2 is a benzoimidazolyl group; R8 is -H; and R9 is -fluoro. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, Ar2 is a benzoimidazolyl group; R8 is -H; and R9 is -iodo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Ar2 is a benzoimidazolyl group; R8 is -halo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R3 is -chloro; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S

configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R3 is -bromo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S

configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Ar2 is a benzoimidazolyl group; R3 is -fluoro; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S

configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -iodo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzoimidazolyl group; R8 is -halo, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzoimidazolyl group; R8 is -chloro, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzoimidazolyl group; R8 is -bromo, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzoimidazolyl group; R8 is -fluoro, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzoimidazolyl group; R8 is -iodo, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; ; Are is a benzoimidazolyl group; R8 is -H; and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzoimidazolyl group; R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzoimidazolyl group; R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzoimidazolyl group; R8 is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Ar2 is a benzoimidazolyl group; R8 is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzoimidazolyl group; R8 is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzoimidazolyl group; R3 is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzoimidazolyl group; R8 is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Ar2 is a benzoimidazolyl group; R8 is -tent-butyl; and R9 is -H.
In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F;

is -tent-butyl; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -H; and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is R, is -F; Are is a benzoimidazolyl group; R8 is -H; and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or, -I; ; Are is a benzoimidazolyl group; and R8 and R9 are -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzoimidazolyl group; and R8 and R9 are -H.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -H; and R9 is -halo.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, Are is a benzoimidazolyl group; R3 is -H; and R9 is -chloro.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, Are is a benzoimidazolyl group; R8 'S-H; and R9 is -bromo.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, Ar2 is a benzoimidazolyl group; R8 is -H; and R9 is -fluoro.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, Are is a benzoimidazolyl group; R8 is -H; and R9 is -iodo.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -halo; and R9 is -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -chloro; and R9 is -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -bromo; and R9 is -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -fluoro; and R9 is -H.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -iodo; and R9 is -H.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Ar2 is a benzoimidazolyl group; R$ is -halo, and R9 is -H.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzoimidazolyl group; R$ is -chloro, and R9 is -H.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzoimidazolyl group; R3 is -bromo, and R9 is -H.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzoimidazolyl group; R8 is -fluoro, and R9 is -H.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzoimidazolyl group; R8 is -iodo, and R9 is -H.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; ; Are is a benzoimidazolyl group; R$ is -H; and R9 is -CH3.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzoimidazolyl group; R8 is -H, and R9 is -CH3.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R$ is -CH3; and R9 is -H.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzoimidazolyl group; R$ is -CH3, and R9 is -H.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R3 is -H; and R9 is -CF3.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzoimidazolyl group; R3 is -H; and R9 is -CF3.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R$ is -CF3; and R9 is -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzoimidazolyl group; Rg is -CF3; and R9 is -H.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -H; and R9 is -OCH2CH3.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzoimidazolyl group; R8 is -H; and R9 is -OCH2CH3.
In another embodiment Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, Art Art is a pyrimidinyl group, p is 0; R3 is -H; Rt is -F; Are is a benzoimidazolyl group; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -tert-butyl; and R9 is -H.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is -F;
Are is a benzoimidazolyl group; R8 is -tert-butyl; and R9 is -H.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is R1 is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -H; and R9 is -tert-butyl.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is R1 is -F. Are is a benzoimidazolyl group; R8 is -H; and R9 is -tert-butyl.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R1 is -F, -Cl, -Br, or, -I; ; Ar2 is a benzoimidazolyl group; and R8 and R9 are -H.
In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R1 is -F;
Are is a benzoimidazolyl group; and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R1 is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R1 is -F, Are is a benzoimidazolyl group; R8 is -H; and R9 is -chloro. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; Rt is -F, Ar2 is a benzoimidazolyl group; R8 is -H; and R9 is -bromo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; Rt is -F, Are is a benzoimidazolyl group; R8 is -H; and R9 is -fluoro. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; Rt is -F, Are is a benzoimidazolyl group; R8 is -H; and R9 is -iodo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; Rt is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -halo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; Rt is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -chloro; and R9 is -H.
In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; Rt is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -bromo; and R9 is -H.
In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; Rt is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -fluoro; and R9 is -H.
In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Arl is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R$ is -iodo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzoimidazolyl group; R8 is -halo, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzoimidazolyl group; R$ is -chloro, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Arz is a benzoimidazolyl group; R$ is -bromo, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzoimidazolyl group; R8 is -fluoro, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzoimidazolyl group; R8 is -iodo, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; ; Are is a benzoimidazolyl group; R8 is -H; and R9 is -CH3.
In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Arl is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzoimidazolyl group; R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Ar2 is a benzoimidazolyl group; R8 is -CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzoimidazolyl group; R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S

configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F.
Are is a benzoimidazolyl group; R8 is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzoimidazolyl group; R8 is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Arl is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -H; and R9 is -OCH2CH3.
In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzoimidazolyl group; R8 is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment Arl is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzoimidazolyl group; R8 is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -tent-butyl; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S

configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
R8 is -tert-butyl; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is R, is -F, -Cl, -Br, or -I; Are is a benzoimidazolyl group; R8 is -H; and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R1 is is -F; Are is a benzoimidazolyl group; R3 is -H; and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or, -I; ; Are is a benzooxazolyl group; and R8 and R9 are -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; RI is -F; Ar2 is a benzooxazolyl group; and R8 and R9 are -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -H; and R9 is -halo.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, Ar2 is a benzooxazolyl group; R8 is -H; and R9 is -chloro.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, Ar2 is a benzooxazolyl group; R8 'S-H; and R9 is -bromo.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, Ar2 is a benzooxazolyl group; R8 is -H; and R9 is -fluoro.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, Ar2 is a benzooxazolyl group; R8 is -H; and R9 is -iodo.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -halo; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -chloro; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -bromo; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -fluoro; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -iodo; and R9 is -H.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -H; R, is -F; Ar2 is a benzooxazolyl group; R8 is -halo, and R9 is -H.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -H; R, is -F; Are is a benzooxazolyl group; R8 is -chloro, and R9 is -H.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -H; R, is -F; Are is a benzooxazolyl group; R8 is -bromo, and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F; Ar2 is a benzooxazolyl group; R3 is -fluoro, and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F; Are is a benzooxazolyl group; R8 is -iodo, and R9 is -H.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; ; Are is a benzooxazolyl group; R8 is -H; and R9 is -CH3.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F; Are is a benzooxazolyl group; R8 is -H, and R9 is -CH3.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -CH3; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F; Ar2 is a benzooxazolyl group; R8 is -CH3, and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Ar2 is a benzooxazolyl group; R8 is -H; and-R9 is -CF3.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F; Ar2 is a benzooxazolyl group; R8 is -H; and R9 is -CF3.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -CF3; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F; Ar2 is a benzooxazolyl group; R8 is -CF3; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -H; and R9 is -OCH2CH3.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -H; R, is -F; Ar2 is a benzooxazolyl group; R8 is -H; and R9 is -OCH2CH3.
In another embodiment Arl is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, Art Art is a pyridyl group, n is 0; R3 is -H; R, is -F;
Are is a benzooxazolyl group; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -tert-butyl; and R9 is -H.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -H; R, is -F; Ar2 is a benzooxazolyl group; R3 is -tert-butyl; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -H; R, is R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -H; and R9 is -tent-butyl.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -H; R, is R, is -F;
Are is a benzooxazolyl group; R8 is -H; and R9 is -tert-butyl.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or, -I; ; Ar2 is a benzooxazolyl group; and R3 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzooxazolyl group; and R$ and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, Ar2 is a benzooxazolyl group; R8 is -H; and R9 is -chloro. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F, Ar2 is a benzooxazolyl group; R8 is -H; and R9 is -bromo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F, Ar2 is a benzooxazolyl group; R3 is -H; and R9 is -fluoro. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F, Ar2 is a benzooxazolyl group; R8 is -H; and R9 is -iodo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -halo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -chloro; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R3 is -bromo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -fluoro; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -iodo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzooxazolyl group; R8 is -halo, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzooxazolyl group; R8 is -chloro, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzooxazolyl group; R8 is -bromo, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzooxazolyl group; R8 is -fluoro, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzooxazolyl group; R8 is -iodo, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; ; Are is a benzooxazolyl group; R8 is -H; and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzooxazolyl group; R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3a R, is -F, -Cl, -Br, or -I; Ar2 is a benzooxazolyl group; R8 is -CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzooxazolyl group; R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R$ is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzooxazolyl group; R8 is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R$ is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzooxazolyl group; R$ is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzooxazolyl group; R8 is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment Arl is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S

configuration.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F;
Ar2 is a benzooxazolyl group; R8 is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -tent-butyl; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is -F;

is -tert-butyl; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyridyl group, n is 0; R3 is -CH3; R, is R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -H; and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyridyl group, n is 0; R3 is -CH3; R, is R, is -F; Are is a benzooxazolyl group; R$ is -H; and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or, -I; ; Are is a benzooxazolyl group; and R8 and R9 are -H.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzooxazolyl group; and Rg and R9 are -H.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -H; and R9 is -halo.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is -F, Are is a benzooxazolyl group; R8 'S-H; and R9 is -chloro.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is -F, Ara is a benzooxazolyl group; R8 is -H; and R9 is -bromo.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is -F, Are is a benzooxazolyl group; R8 is -H; and R9 is -fluoro.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is -F, Ara is a benzooxazolyl group; R8 is -H; and R9 is -iodo.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Ara is a benzooxazolyl group; R8 is -halo; and R9 is -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -chloro; and R9 is -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -bromo; and R9 is -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -fluoro; and R9 is -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -iodo; and R9 is -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is -F;
Ara is a benzooxazolyl group; R8 is -halo, and R9 is -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is -F;
Ara is a benzooxazolyl group; R8 is -chloro, and R9 is -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is -F;
Ara is a benzooxazolyl group; R8 is -bromo, and R9 is -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is -F;
Ar2 is a benzooxazolyl group; R8 is -fluoro, and R9 is -H.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R1 is -F;
Are is a benzooxazolyl group; R8 is -iodo, and R9 is -H.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; ; Are is a benzooxazolyl group; R8 is -H; and R9 is -CH3.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzooxazolyl group; R8 is -H, and R9 is -CH3.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -CH3; and R9 is -H.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzooxazolyl group; R8 is -CH3, and R9 is -H.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R$ is -H; and R9 is -CF3.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzooxazolyl group; R8 is -H; and R9 is -CF3.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -CF3; and R9 is -H.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzooxazolyl group; R8 is -CF3; and R9 is -H.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -H; and R9 is -OCH2CH3.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzooxazolyl group; R8 is -H; and R9 is -OCH2CH3.
In another embodiment Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -OCH2CH3; and R9 is -H.
In another embodiment, Art Art is a pyrimidinyl group, p is 0; R3 is -H; R, is -F; Ar2 is a benzooxazolyl group; R8 is -OCH2CH3; and R9 is -H.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F, -Cl, -Br, or -I; Ar2 is a benzooxazolyl group; R8 is -tert-butyl; and R9 is -H.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is -F;
Are is a benzooxazolyl group; R8 is -tent-butyl; and R9 is -H.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -H; R, is R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -H; and R9 is -tent-butyl.
In another embodiment, Arl is a pyrimidinyl group, p is 0; R3 is -H; R, is R, is -F. Are is a benzooxazolyl group; R3 is -H; and R9 is -tert-butyl.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or, -I; Are is a benzooxazolyl group; and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzooxazolyl group; and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Ara is a benzooxazolyl group; R3 is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R3 is -H; and R9 is -chloro. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Ara is a benzooxazolyl group; R8 is -H; and R9 is -bromo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Ar2 is a benzooxazolyl group; R3 is -H; and R9 is -fluoro. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R3 is -H; and R9 is -iodo. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S

configuration.
In another embodiment, Arl is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, Are is a benzooxazolyl group; R8 is -H; and R9 is -chloro. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, Are is a benzooxazolyl group; R8 is -H; and R9 is -bromo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, Are is a benzooxazolyl group; R8 is -H; and R9 is -fluoro. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, Are is a benzooxazolyl group; R8 is -H; and R9 is -iodo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Ar2 is a benzooxazolyl group; R8 is -halo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Ar2 is a benzooxazolyl group; R8 is -chloro; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R$ is -bromo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S

configuration.
In another embodiment, Arl is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -fluoro; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S

configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R$ is -iodo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S

configuration.
In another embodiment, Arl is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzooxazolyl group; R$ is -halo, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzooxazolyl group; R8 is -chloro, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzooxazolyl group; R3 is -bromo, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Arl is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzooxazolyl group; R$ is -fluoro, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Arl is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzooxazolyl group; R8 is -iodo, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; ; Are is a benzooxazolyl group; R8 is -H; and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzooxazolyl group; R8 is -H, and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Ar2 is a benzooxazolyl group; R8 is -CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Ar2 is a benzooxazolyl group; R8 is -CH3, and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Ar2 is a benzooxazolyl group; R8 is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F.
Are is a benzooxazolyl group; R8 is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Arl is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R$ is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S

configuration.
In another embodiment, Arl is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzooxazolyl group; R8 is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -H; and R9 is -OCH2CH3.
In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzooxazolyl group; R$ is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment Art is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R$ is -OCH2CH3; and R9 is -H.
In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F;
Are is a benzooxazolyl group; R8 is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Ar, is a pyrimidinyl group, p is 0; R3 is -CH3; R, is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -tent-butyl; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Arl is a pyrimidinyl group, p is 0; R3 is -CH3; R1 is -F;
R8 is -tert-butyl; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar1 is a pyrimidinyl group, p is 0; R3 is -CH3; R1 is is -F, -Cl, -Br, or -I; Are is a benzooxazolyl group; R8 is -H; and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R
configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Arl is a pyrimidinyl group, p is 0; R3 is -CH3; R1 is is -F; Ar2 is a benzooxazolyl group; R8 is -H; and R9 is -tert-butyl. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
4.8 The Compounds of Formula (IVb) The present invention also encompasses compounds of formula (IVb):
Ar1 N

I
(~)X

Are (IVb) and pharmaceutically acceptable salts thereof, where Art, Ar2, A, R3 and x are defined above for the Benzoazolylpiperazine Compounds of formula (IVb).
In one embodiment, Art is a pyridyl group.

In another embodiment, Art is a pyrimidinyl group.
In another embodiment, n or p is 0.
In another embodiment, n or p is 1.
In another embodiment, x is 0.

In another embodiment, x is 1.

In another embodiment, R1 is -F.
In another embodiment, R1 is -Cl.
In another embodiment, R1 is -Br.
In another embodiment, R1 is -I.
In another embodiment, R1 is -(C1-C6)alkyl.
In another embodiment, R1 is -CH3.
In another embodiment, R1 is -NO2.
another embodiment, R1 is -CN.
In another embodiment, R1 is -OH.
In another embodiment, R1 is -OCH3.

In another embodiment, R1 is -NH2.
In another embodiment, R1 is -C(halo)3.
In another embodiment, R1 is -CH(halo)2.
In another embodiment, R1 is -CH2(halo).
In another embodiment, n and p are 1 and R2 is -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2.
In another embodiment, n and p are 1 and R2 is -(C1-C10)alkyl, -(CZ
C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(Cg C14)bicycloalkyl, -(C$
C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3-to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups.
In another embodiment, n and p are 1 and R2 is -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;

In another embodiment, x is 1 and A is -C(O)N(R4)-.

In another embodiment, x is 1, A is -C(O)N(R4)-, and R4 is -H.
In another embodiment, x is 1, A is -C(O)N(R4)-, and R4 is -CH3.
In another embodiment, x is 1 and A is -C(S)N(R4)-.
In another embodiment, x is 1, A is -C(S)N(R4)-, and R4 is -H.
In another embodiment, x is 1, A is -C(S)N(R4)-, and R4 is -CH3.
In another embodiment, Are is a benzothiazolyl group.

In another embodiment, Are is a benzoimidazolyl group.
In another embodiment, Are is a benzooxazolyl group.
In another embodiment, R8 and R9 are each independently -H, halo, -(C,-C6)alkyl, -O(C1-C6)alkyl, -C(halo)3, -CH(halo)2, or -CH2(halo).

In another embodiment, at least one of R8 or R9 is -H.

In another embodiment, Art is a pyridyl group, n is 0; R1 is -F, -Cl, -Br, or -I;
R4 is -H; Are is a benzothiazolyl group; and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridyl group, n is 0; R1 is -F; R4 is -H; Are is a benzothiazolyl group and R8 and R9 are -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R1 is -F, -Cl, -Br, or -I;
Are is a benzothiazolyl group; R8 is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R1 is -F, -Cl, -Br, or -I;
Are is a benzothiazolyl group; R8 is -H; and R9 is -chloro. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R1 is -F, -Cl, -Br, or -I;
Are is a benzothiazolyl group; R8 is -H; and R9 is -bromo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R1 is -F, -Cl, -Br, or -I;
Are is a benzothiazolyl group; R8 is -H; and R9 is -fluoro. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyridyl group, n is 0; R, is -F, -Cl, -Br, or -I;
Are is a benzothiazolyl group; R$ is -H; and R9 is -iodo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyridyl group, n is 0; R, is -F; Are is a benzothiazolyl group; R$ is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R, is -F; Ar2 is a benzothiazolyl group; R3 is -H; and R9 is -chloro. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyridyl group, n is 0; R, is -F; Are is a benzothiazolyl group; R3 is -H; and R9 is -bromo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R, is -F; Are is a benzothiazolyl group; R8 is -H; and R9 is -fluoro. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R, is -F; Ar2 is a benzothiazolyl group; R8 is -H; and R9 is -iodo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R, is -F, -Cl, -Br, or -I;
Are is a benzothiazolyl group; R8 is -halo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R, is -F, -Cl, -Br, or -I;
Are is a benzothiazolyl group; R$ is -chloro; and R9 is -H.
In another embodiment, Art is a pyridyl group, n is 0; R, is -F, -Cl, -Br, or -I;
Ar2 is a benzothiazolyl group; R8 is -bromo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R, is -F, -Cl, -Br, or -I;
Are is a benzothiazolyl group; R$ is -fluoro; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R, is -F, -Cl, -Br, or -I;
Are is a benzothiazolyl group; R$ is -iodo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R, is -F; Ar2 is a benzothiazolyl group; R8 is -halo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Ar, is a pyridyl group, n is 0; R, is -F; Are is a benzothiazolyl group; R8 is -chloro; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R, is -F; Are is a benzothiazolyl group; R$ is -bromo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R, is -F; Ar2 is a benzothiazolyl group; R$ is -fluoro; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R, is -F; Are is a benzothiazolyl group; R8 is -iodo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R, is -F, -Cl, Br, or -I;
Are is a benzothiazolyl group; R8 is -H; and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R, is -F; Are is a benzothiazolyl group; R8 is -H; and R9 is -CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R, is -F, -Cl, Br, or -I;
Are is a benzothiazolyl group; R8 is -CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Arl is a pyridyl group, n is 0; R, is -F; Are is a benzothiazolyl group; R8 is -CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R, is -F, -Cl, Br, or -I;
Are is a benzothiazolyl group; R8 is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R, is -F; Are is a benzothiazolyl group; R8 is -H; and R9 is -CF3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R, is -F, -Cl, Br, or -I;
Are is a benzothiazolyl group; R8 is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Arl is a pyridyl group, n is 0; R, is -F; Ara is a benzothiazolyl group; R8 is -CF3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R, is -F, -Cl, Br, or -I;
Are is a benzothiazolyl group; R3 is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.
In another embodiment, Art is a pyridyl group, n is 0; R, is -F; Are is a benzothiazolyl group; R8 is -H; and R9 is -OCH2CH3. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R, is -F, -Cl, Br, or -I;
Are is a benzothiazolyl group; R8 is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S
configuration.

In another embodiment, Art is a pyridyl group, n is 0; R, is -F; Are is a benzothiazolyl group; R8 is -OCH2CH3; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R, is -CH3; Are is a benzothiazolyl group; R8 is -H; and R9 is -halo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Ar, is a pyridyl group, n is 0; R, is -CH3; Are is a benzothiazolyl group; R8 is -H; and R9 is -chloro. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Arl is a pyridyl group, n is 0; R, is -CH3; Are is a benzothiazolyl group; R8 is -H; and R9 is -bromo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R, is -CH3; Are is a benzothiazolyl group; R8 is -H; and R9 is -fluoro. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R, is -CH3; Are is a benzothiazolyl group; R8 is -H; and R9 is -iodo. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R, is -CH3; Are is a benzothiazolyl group; R8 is -halo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R, is -CH3; Are is a benzothiazolyl group; R8 is -chloro; and R9 is -H. In another embodiment, the carbon atom to which the R3~group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.

In another embodiment, Art is a pyridyl group, n is 0; R, is -CH3; Are is a benzothiazolyl group; R8 is -bromo; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R, is -CH3; Are is a benzothiazolyl group; R8 is -fluoro; and R9 is -H. In another embodiment, the carbon atom to which the R3 group is attached has the R configuration. In another embodiment, the carbon atom to which the R3 group is attached has the S configuration.
In another embodiment, Art is a pyridyl group, n is 0; R, is -CH3; Are is a benzothiazolyl group; R8 is -iodo; and R9 is -H. In another embodiment, the carbon atom to DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.
CECI EST LE TOME DE

NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.

NOTE: For additional volumes please contact the Canadian Patent Office.

Claims (35)

1. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein Ar1 is A is R1 is -Cl, -Br, -I, -(C1-C6)alkyl, -NO2, -CN, -OH, -OCH3, -NH2, -C(halo)3, -CH(halo)2, or -CH2(halo);
each R2 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
each R3 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
R4 is -H or -(C1-C6)alkyl;
each R5 is independently -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R6 is independently -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R7 is independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH2(halo), or -CH(halo)2;
R8 and R9 are each independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each -halo is -F, -Cl, -Br, or -I;
n is an integer ranging from 0 to 3;
p is an integer ranging from 0 to 2;
m is 0 or 1; and x is 0 or 1.
2. The compound of claim 1, wherein Ar1 is a pyridyl group.
3. The compound of any one of claims 1 or 2, wherein x is 1 and A is -C(O)N(R4)-.
4. The compound of any one of claims 1 or 2, wherein x is 0.
5. The compound of any one of claims 1-4, wherein n or p is 0.
6. The compound of any one of claims 1-4, wherein n or p is 1.
7. The compound of claim 1, wherein Ar1 is a pyrimidinyl group.
8. The compound of claim 7, wherein x is 1 and A is -C(O)N(R4)-.
9. The compound of any one of claims 1 or 2, wherein:
R1 is -CH3, -CF3, -Cl, -Br, or -I;
m is 0;
n or p is 0;
x is 1;
A is -C(O)-N(R4)-;
R4 is -H;
R8 is -H; and R9 is -CH3, -CF3, -OCH2CH3, -tert-butyl, -Cl, -Br, or -F.
10. The compound of claim 9, wherein R1 is -CH3 and R9 is -Cl, -Br, or -F.
11. The compound of claim 9, wherein R1 is -Cl and R9 is -Cl, -Br, or -F.
12. The compound of any one of claims 1 or 2, wherein:
R1 is -CH3, -CF3, -Cl, -Br, or -I;
m is 1;
R3 is -(C1-C10)alkyl;
n or p is 0;
x is 1;

A is -C(O)-N(R4)-;
R4 is -H;
R8 is -H; and R9 is -CH3, -CF3, -OCH2CH3, -tert-butyl, -Cl, -Br, or -F.
13. The compound of claim 12, wherein R3 is -CH3.
14. The compound of claim 12, wherein R3 is attached to a carbon atom adjacent to a nitrogen atom attached to the -C(O)-N(R4)-group.
15. The compound of claim 14, wherein R1 is -CH3, R3 is -CH3, and R9 is -Cl, -Br;
or -F.
16. The compound of claim 14, wherein R1 is -Cl, R3 is -CH3, and R9 is -Cl, -Br, or -F.
17. The compound of any one of claims 12-16, wherein the carbon to which R3 is attached is in the (R) configuration.
18. The compound of claim 1, wherein m is 1 and the carbon to which R3 is attached is in the (R) configuration.
19. A compound of claim 1, selected from the group consisting of:

and pharmaceutically acceptable salts thereof.
20. A compound of formula:
or a pharmaceutically acceptable salt thereof, wherein Ar1 is A is R1 is -H, -halo, -(C1-C6)alkyl, -NO2, -CN, -OH, -OCH3, -NH2, -C(halo)3, -CH(halo)2, or -CH2(halo);
each R2 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
each R3 is independently;
(a) -halo, -CN, -OH, -O(C)-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
R4 is -H or -(C1-C6)alkyl;
each R5 is independently -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R6 is independently -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R7 is independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH2(halo), or -CH(halo)2;
R8 and R9 are each independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;

each -halo is -F, -Cl, -Br, or -I;
p is an integer ranging from 0 to 2;
m is 0 or 1; and x is 0 or 1.
21. A compound of formula:
or a pharmaceutically acceptable salt thereof, wherein Ar1 is R1 is -Cl, -Br, -I, -(C1-C6)alkyl, -NO2, -CN, -OH, -OCH3, -NH2, -C(halo)3, -CH(halo)2, or -CH2(halo);
each R2 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
each R3 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
each R5 is independently -CN, -OH, -halo, -N3, NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R6 is independently -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, Or -S(O)2R7;
each R7 is independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH2(halo), or -CH(halo)2;
R8 and R9 are each independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
R10 is -(C1-C4)alkyl;
each -halo is -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 3;
p is an integer ranging from 0 to 2; and m is 0 or 1.
22. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein Ar1 is A is R1 is -H, -halo, -(C1-C6)alkyl, -NO2, -CN, -OH, -OCH3, -NH2, -C(halo)3, -CH(halo)2, or -CH2(halo);
each R2 is independently:

(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
each R3 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
R4 is -H or -(C1-C6)alkyl;
each R5 is independently -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R6 is independently -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R7 is independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH2(halo), or -CH(halo)2;
R8 and R9 are each independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
R10 is -H or -(C1-C4)alkyl;
each -halo is -F, -Cl, -Br, or -I;
p is an integer ranging from 0 to 2;
in is 0 or 1; and x is 0 or 1.
23. A compound selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
24. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein Ar1 is A is R1 is -Cl, -Br, -I, -(C1-C6)alkyl, -NO2, -CN, -OH, -OCH3, -NH2, -C(halo)3, -CH(halo)2, or -CH2(halo);
each R2 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C10)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
each R3 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
R4 is -H or -(C1-C6)alkyl;
each R5 is independently -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R6 is independently -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R7 is independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH2(halo), or -CH(halo)2;
R8 and R9 are each independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each -halo is -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 3;
p is an integer ranging from 0 to 2;
m is 0 or 1; and x is 0 or 1.
25. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein Ar1 is A is R1 is -H, -halo, -(C1-C6)alkyl, -NO2, -CN, -OH, -OCH3, -NH2, -C(halo)3, -CH(halo)2, or -CH2(halo);

each R2 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl; (C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, or-(C14)aryl, each of which is unsubstituted or substituted with one or more R6 groups;
each R3 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl; (C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
R4 is -H or -(C1-C6)alkyl;
each R5 is independently -CN, -OH, -halo, -N3, -NO2, N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R6 is independently -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R7 is independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH2(halo), or -CH(halo)2;
R8 and R9 are each independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each -halo is -F, -Cl, -Br, or -I;
p is an integer ranging from 0 to 2;
m is 0 or 1; and x is 0 or 1.
26. A compound selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
27. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein Ar1 is Ar2 is R1 is -halo, -(C1-C6)alkyl, NO2, -CN, -OH, -OCH3, -NH2, -C(halo)3, -CH(halo)2, or -CH2(halo);
each R2 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl; (C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
R3 is -H or -CH3:
each R5 is independently -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R6 is independently -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R7 is independently -H, -(C1 -C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH2(halo), or -CH(halo)2;
R8 and R9 are each independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -C(halo)3, -CH(halo)2, -CH2(halo), -OC(halo)3, -OCH(halo)2, -OCH2(halo), -CN, -OH, -halo, -N3, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each -halo is -F, -Cl, -Br, or -I;
n is an integer ranging from 0 to 3; and p is an integer ranging from 0 to 2.
28. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein Ar1 is A is R1 is -halo, -(C1-C6)alkyl, -NO2, -CN, -OH, -OCH3, -NH2, -C(halo)3, -CH(halo)2, or -CH2(halo);
each R2 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;

R3 is -CH3;
R4 is -H or -(C1-C6)alkyl;
each R5 is independently -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R6 is independently -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R7 is independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH2(halo), or -CH(halo)2;
R8 and R9 are each independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -C(halo)3, -CH(halo)2, -CH2(halo), -OC(halo)3, -OCH(halo)2, -OCH2(halo), -CN, -OH, -halo, -N3, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each -halo is -F, -Cl, -Br, or -I;
n is an integer ranging from 0 to 3;
p is an integer ranging from 0 to 2; and x is 0 or 1;

when x is 0, Ar2 is and when x is 1, Ar2 is
29. A composition comprising the compound or a pharmaceutically acceptable salt of the compound of any one of claims 1 to 28 and a pharmaceutically acceptable vehicle.
30. A composition comprising:

(i) a pharmaceutically-acceptable amount of a compound of formula:
or a pharmaceutically acceptable salt thereof, wherein Ar1 is Ar2 is R1 is -halo, -(C1-C6)alkyl, -NO2, -CN, -OH, -OCH3, -NH2, -C(halo)3, -CH(halo)2, or -CH2(halo);
each R2 is independently:
(a) -halo, -CN, -OH, -O(C1-C6)alkyl, -NO2, or -NH2;
(b) -(C1-C10)alkyl, -(C2-C10)alkenyl, -(C2-C10)alkynyl, -(C3-C10)cycloalkyl, -(C8-C14)bicycloalkyl, -(C8-C14)tricycloalkyl, -(C5-C10)cycloalkenyl,-(C8-C14)bicycloalkenyl, -(C8-C14)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R5 groups; or (c) -phenyl, -naphthyl, -(C14)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R6 groups;
R3 is -H or -CH3:
each R5 is independently -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R6 is independently -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH(halo)2, -CH2(halo), -CN, -OH, -halo, -N3, -NO2, -N(R7)2, -CH=NR7, -NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each R7 is independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -(C3-C5)heterocycle, -C(halo)3, -CH2(halo), or -CH(halo)2;
R8 and R9 are each independently -H, -(C1-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C8)cycloalkyl, -(C5-C8)cycloalkenyl, -phenyl, -C(halo)3, -CH(halo)2, -CH2(halo), -OC(halo)3, -OCH(halo)2, -OCH2(halo), -CN, -OH, -halo, -N3, -N(R7)2, -CH=NR7, NR7OH, -OR7, -COR7, -C(O)OR7, -OC(O)R7, -OC(O)OR7, -SR7, -S(O)R7, or -S(O)2R7;
each -halo is -F, -Cl, -Br, or -I;
n is an integer ranging from 0 to 3; and p is an integer ranging from 0 to 2; and (ii) a pharmaceutically acceptable carrier or excipient.
31. The use of a pharmaceutically acceptable amount of a composition or a compound or a pharmaceutically acceptable salt of the compound of any one of claims 1 to 30 for the manufacture of a medicament for treating or preventing a disorder in an animal, the disorder being pain, urinary incontinence, ulcer, irritable-bowel syndrome, inflammatory-bowel disease, addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, seizure, pruritic condition, psychosis, cognitive disorder, memory deficit, restricted brain function, Huntingdon's chorea, amyotrophic lateral sclerosis, retinopathy, muscle spasm, migraine, vomiting, dyskinesia or depression.
32. The use of a pharmaceutically acceptable amount of a composition or a compound or a pharmaceutically acceptable salt of the compound of any one of claims 1 to 30 for the manufacture of a medicament for treating or preventing a disorder in an animal, the disorder being pain, urinary incontinence, ulcer, irritable-bowel syndrome, or inflammatory-bowel disease.
33. An in vitro method for inhibiting VR1 function in a cell comprising contacting a cell capable of expressing VR1 with a pharmaceutically acceptable amount of the compound or composition or pharmaceutically acceptable salt of the compound of any one of claims 1 to 30.
34. A method for preparing a composition comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of any one of claims 1 to 28, together with a pharmaceutically acceptable carrier or excipient.
35. Use of a pharmaceutically acceptable amount of the compound or composition or pharmaceutically acceptable salt of the compound of any one of claims 1 to 30 for the manufacture of a medicament for inhibiting VR1 function in a cell.
CA2511509A 2002-12-24 2003-12-22 Benzoazolylpiperazine derivatives having vr1 antagonist activity Expired - Fee Related CA2511509C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US43591702P 2002-12-24 2002-12-24
US60/435,917 2002-12-24
US45962603P 2003-04-03 2003-04-03
US60/459,626 2003-04-03
US47385603P 2003-05-29 2003-05-29
US60/473,856 2003-05-29
PCT/US2003/041100 WO2004058754A1 (en) 2002-12-24 2003-12-22 Benzoazolypiperazine derivatives having mglur1- and mglur5-antagonistic activity

Publications (2)

Publication Number Publication Date
CA2511509A1 CA2511509A1 (en) 2004-07-15
CA2511509C true CA2511509C (en) 2012-08-14

Family

ID=32686087

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2511509A Expired - Fee Related CA2511509C (en) 2002-12-24 2003-12-22 Benzoazolylpiperazine derivatives having vr1 antagonist activity

Country Status (26)

Country Link
US (5) US7582635B2 (en)
EP (1) EP1583763B1 (en)
JP (4) JP4680774B2 (en)
KR (1) KR20050087867A (en)
CN (1) CN100560584C (en)
AR (1) AR043324A1 (en)
AT (1) ATE390423T1 (en)
AU (1) AU2003297506A1 (en)
BR (1) BR0317757A (en)
CA (1) CA2511509C (en)
CY (1) CY1108155T1 (en)
DE (1) DE60320033T2 (en)
DK (1) DK1583763T3 (en)
EA (1) EA200501022A1 (en)
ES (1) ES2303609T3 (en)
HK (1) HK1090033A1 (en)
HR (1) HRP20050666B1 (en)
IL (1) IL169378A0 (en)
MX (1) MXPA05006869A (en)
NO (1) NO20053582L (en)
NZ (1) NZ541415A (en)
PL (1) PL377514A1 (en)
PT (1) PT1583763E (en)
RS (1) RS20050498A (en)
SI (1) SI1583763T1 (en)
WO (1) WO2004058754A1 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7867516B2 (en) 2001-01-29 2011-01-11 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
EP2130536B1 (en) * 2002-03-13 2013-05-08 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
JP2006505570A (en) * 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド Benzimidazole derivatives and their use as vanilloid receptor ligands
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
ES2327684T3 (en) * 2003-07-24 2009-11-02 Euro-Celtique S.A. HETEROARIL-TETRAHIDROPIRIDILO COMPOUNDS USEFUL FOR THE TREATMENT OR PREVENTION OF PAIN.
PL1867644T3 (en) * 2003-07-24 2009-10-30 Euro Celtique Sa Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
US7754711B2 (en) * 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
JP5148110B2 (en) * 2003-08-01 2013-02-20 ユーロ−セルティーク エス．エイ． Useful therapeutics for pain
US20050124625A1 (en) * 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
SE0303418D0 (en) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
SE0303419D0 (en) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 11
SE0303489D0 (en) * 2003-12-19 2003-12-19 Astrazeneca Ab New use VII
SE0303488D0 (en) * 2003-12-19 2003-12-19 Astrazeneca Ab New use 1X
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
EP1752143A1 (en) * 2005-08-08 2007-02-14 NewThera Novel uses for drugs targeting glutamine synthetase
PE20080707A1 (en) * 2006-06-01 2008-05-22 Wyeth Corp BENZOXAZOLE AND BENZOTHIAZOLE DERIVATIVES AS 5-HYDROXITRIPTAMINE-6 BINDERS
TW200814968A (en) * 2006-06-07 2008-04-01 Combinatorx Inc Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein levels
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20080153845A1 (en) * 2006-10-27 2008-06-26 Redpoint Bio Corporation Trpv1 antagonists and uses thereof
NZ579820A (en) * 2007-04-27 2011-01-28 Purdue Pharma Lp Therapeutic agents useful for treating pain
AU2011226773C1 (en) * 2007-04-27 2012-07-26 Purdue Pharma L.P. TRPV1 antagonists and uses thereof
CA2685266C (en) * 2007-04-27 2014-01-28 Purdue Pharma L.P. Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal
CN102014957B (en) 2008-04-21 2014-12-10 奥德纳米有限公司 Auris formulations for treating otic diseases and conditions
WO2010011605A2 (en) 2008-07-21 2010-01-28 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US8921373B2 (en) 2010-06-22 2014-12-30 Shionogi & Co., Ltd. Compounds having TRPV1 antagonistic activity and uses thereof
US9474454B2 (en) * 2010-10-20 2016-10-25 Advanced Mri Technologies Llc MRI using faster multiplexed echo planar imaging (EPI) pulse sequences
WO2012102204A1 (en) 2011-01-28 2012-08-02 オリンパスメディカルシステムズ株式会社 Capsule endoscope system
US9918980B2 (en) 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US10736889B2 (en) 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
SI2701707T1 (en) * 2011-04-29 2021-02-26 Rutgers, The State University Of New Jersey Method of treating dyskinesia
WO2012158844A1 (en) 2011-05-17 2012-11-22 Shionogi & Co., Ltd. Heterocyclic compounds
EP2723732B1 (en) * 2011-06-22 2017-01-18 Purdue Pharma LP Trpv1 antagonists including dihydroxy substituent and uses thereof
AU2012293417A1 (en) 2011-08-10 2013-05-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
US11648561B2 (en) 2012-02-13 2023-05-16 Neumodx Molecular, Inc. System and method for processing and detecting nucleic acids
CN104254595A (en) 2012-02-13 2014-12-31 纽莫德克斯莫勒库拉尔公司 Microfluidic cartridge for processing and detecting nucleic acids
US11485968B2 (en) 2012-02-13 2022-11-01 Neumodx Molecular, Inc. Microfluidic cartridge for processing and detecting nucleic acids
US9637775B2 (en) 2012-02-13 2017-05-02 Neumodx Molecular, Inc. System and method for processing biological samples
US8924211B2 (en) * 2012-07-09 2014-12-30 Nuance Communications, Inc. Detecting potential significant errors in speech recognition results
US9064492B2 (en) 2012-07-09 2015-06-23 Nuance Communications, Inc. Detecting potential significant errors in speech recognition results
WO2014066376A1 (en) 2012-10-25 2014-05-01 Neumodx Molecular, Inc. Method and materials for isolation of nucleic acid materials
US9054800B2 (en) 2013-09-11 2015-06-09 Symbol Technologies, Llc Staging a mobile device with visible light communication
BR112016012359A2 (en) 2013-12-02 2017-08-08 Mastercard International Inc METHOD AND SYSTEM FOR SECURE TRANSMISSION OF REMOTE NOTIFICATION SERVICE MESSAGES TO MOBILE DEVICES WITHOUT SECURE ELEMENTS
US10275767B2 (en) 2014-10-21 2019-04-30 Mastercard International Incorporated Method and system for generating cryptograms for validation in a webservice environment
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CA3025260A1 (en) * 2016-06-23 2017-12-28 Lalit Kumar Sharma Small molecule modulators of pantothenate kinases
AU2017290256A1 (en) 2016-06-29 2019-01-17 Otonomy, Inc. Triglyceride otic formulations and uses thereof
CN106918697B (en) * 2017-02-15 2018-07-31 中国医学科学院北京协和医院 It is a kind of prediction RA curative effect of medication diagnosis marker and its application
JP6991239B2 (en) * 2017-03-30 2022-01-12 エックスダブリューファルマ リミテッド Bicyclic heteroaryl derivatives and their preparation and use
BR112020012875A2 (en) 2017-12-27 2021-01-05 St. Jude Children¿S Research Hospital, Inc. MODULATORS OF SMALL MOLECULES OF PANTOTENATE KINASES
JP2021508738A (en) 2017-12-27 2021-03-11 セント ジュード チルドレンズ リサーチ ホスピタル，インコーポレイティド How to treat disorders associated with CASTOR
JPWO2021070957A1 (en) * 2019-10-09 2021-04-15
CN111887828B (en) * 2020-07-08 2021-05-07 中南大学湘雅医院 Perioperative patient non-contact physiological information monitoring device, computer equipment and storage medium
CN112986452B (en) * 2021-05-10 2021-08-13 湖南慧泽生物医药科技有限公司 Method for determining tandospirone concentration in human plasma
CN113390941B (en) * 2021-06-08 2022-07-01 浙江工业大学 Method for online enrichment determination of organic acid content based on FLM-EKS-CZE of ionic liquid coating
CN114394415B (en) * 2021-12-28 2023-12-12 赤壁市万皇智能设备有限公司 FPC automated production line based on AGV automatic handling system
DE102022104759A1 (en) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-crystal screening method, in particular for the production of co-crystals
CN115936265B (en) * 2023-02-24 2023-06-16 华东交通大学 Robust planning method for electric hydrogen energy system by considering electric hydrogen coupling

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
DE3822792C2 (en) * 1987-07-11 1997-11-27 Sandoz Ag New use of 5HT¶3¶ antagonists
US5198459A (en) * 1987-07-11 1993-03-30 Sandoz Ltd. Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en) * 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5075341A (en) * 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5232934A (en) * 1992-07-17 1993-08-03 Warner-Lambert Co. Method for the treatment of psychomotor stimulant addiction
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
ATE182333T1 (en) * 1994-03-14 1999-08-15 Novo Nordisk As HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE
IT1270594B (en) * 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
DE19514313A1 (en) * 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- and Benzothiazolyloxazolidinone
US5762925A (en) * 1994-11-03 1998-06-09 Sagen; Jacqueline Preventing opiate tolerance by cellular implantation
CA2224517A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US5798360A (en) * 1996-08-01 1998-08-25 Isis Pharmaceuticals, Inc. N-(aminoalkyl)- and/or N-(amidoalkyl)- dinitrogen heterocyclic compositions
DE69819345T2 (en) * 1997-08-20 2004-07-15 The Regents Of The University Of California, Oakland NUCLEIC ACID SEQUENCES ENCODING THE CAPSAICIN RECEPTOR AND POLYPEPTIDES SIMILAR TO THE CAPSAICIN RECEPTOR AND THEIR USE
MXPA00004940A (en) 1997-11-21 2002-10-17 Nps Pharma Inc Metabotropic glutamate receptor antagonists for treating central nervous system diseases.
JPH11199573A (en) 1998-01-07 1999-07-27 Yamanouchi Pharmaceut Co Ltd 5ht3 receptor agonist and new benzothiazole derivative
UA59433C2 (en) 1998-01-27 2003-09-15 Авентіс Фармасьютікалс Продактс Інк. Substituted oxoazaheterocyclyl inhibitors of xa factor
EP0943683A1 (en) * 1998-03-10 1999-09-22 Smithkline Beecham Plc Human vanilloid receptor homologue Vanilrep1
GB9907097D0 (en) * 1999-03-26 1999-05-19 Novartis Ag Organic compounds
SK13532001A3 (en) 1999-04-01 2003-02-04 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors
US6109269A (en) * 1999-04-30 2000-08-29 Medtronic, Inc. Method of treating addiction by brain infusion
US6340681B1 (en) * 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
DE19934799B4 (en) * 1999-07-28 2008-01-24 Az Electronic Materials (Germany) Gmbh Chiral smectic liquid crystal mixture and its use in high contrast active matrix displays
AU6420700A (en) 1999-08-05 2001-03-05 Prescient Neuropharma Inc. Novel 1,4-benzodiazepine compounds and derivatives thereof
IL151045A0 (en) 2000-02-07 2003-04-10 Abbott Gmbh & Co Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
EP1301484A2 (en) 2000-07-20 2003-04-16 Neurogen Corporation Capsaicin receptor ligands
JP2003192673A (en) 2001-12-27 2003-07-09 Bayer Ag Piperazinecarboxamide derivative
EP1472225B1 (en) 2002-02-01 2010-04-28 Euro-Celtique S.A. 2-piperazine-pyridines useful for treating pain
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
DK1556354T3 (en) 2002-06-28 2008-06-02 Euro Celtique Sa Therapeutic piperazine derivatives suitable for the treatment of pain
US7262194B2 (en) * 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
JP2006505570A (en) * 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド Benzimidazole derivatives and their use as vanilloid receptor ligands
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
MXPA06003123A (en) 2003-09-22 2006-05-31 Euro Celtique Sa Therapeutic agents useful for treating pain.
ATE399782T1 (en) 2003-09-22 2008-07-15 Euro Celtique Sa PHENYLCARBOXYRAMIDE COMPOUNDS SUITABLE FOR THE TREATMENT OF PAIN
SI1727801T1 (en) * 2003-12-30 2009-06-30 Euro Celtique Sa Piperazines useful for treating pain

Also Published As

Publication number Publication date
US20120004217A1 (en) 2012-01-05
DK1583763T3 (en) 2008-08-04
US20040186111A1 (en) 2004-09-23
HRP20050666A9 (en) 2007-03-31
DE60320033D1 (en) 2008-05-08
PL377514A1 (en) 2006-02-06
HRP20050666B1 (en) 2009-05-31
CN1753890A (en) 2006-03-29
JP2013209380A (en) 2013-10-10
PT1583763E (en) 2008-06-16
HK1090033A1 (en) 2006-12-15
US20120015954A1 (en) 2012-01-19
HRP20050666A2 (en) 2006-08-31
EP1583763B1 (en) 2008-03-26
US20100004254A1 (en) 2010-01-07
SI1583763T1 (en) 2008-08-31
IL169378A0 (en) 2007-07-04
JP2006513268A (en) 2006-04-20
EP1583763A1 (en) 2005-10-12
US7582635B2 (en) 2009-09-01
MXPA05006869A (en) 2005-09-08
KR20050087867A (en) 2005-08-31
CN100560584C (en) 2009-11-18
DE60320033T2 (en) 2009-04-23
WO2004058754A1 (en) 2004-07-15
JP4680774B2 (en) 2011-05-11
US8536177B2 (en) 2013-09-17
US9434721B2 (en) 2016-09-06
CA2511509A1 (en) 2004-07-15
NZ541415A (en) 2008-11-28
EA200501022A1 (en) 2006-02-24
NO20053582L (en) 2005-09-07
JP2011016826A (en) 2011-01-27
AR043324A1 (en) 2005-07-27
ES2303609T3 (en) 2008-08-16
ATE390423T1 (en) 2008-04-15
CY1108155T1 (en) 2014-02-12
US8604037B2 (en) 2013-12-10
JP6005712B2 (en) 2016-10-12
AU2003297506A1 (en) 2004-07-22
RS20050498A (en) 2007-06-04
JP5437954B2 (en) 2014-03-12
JP5908861B2 (en) 2016-04-26
US20140142112A1 (en) 2014-05-22
BR0317757A (en) 2005-11-22
US8008300B2 (en) 2011-08-30
JP2015083583A (en) 2015-04-30

Similar Documents

Publication Publication Date Title
CA2511509C (en) Benzoazolylpiperazine derivatives having vr1 antagonist activity
CA2528920C (en) Cyclo(hetero)alkenyl compounds useful for treating pain
ZA200502326B (en) Therapeutic piperazine compounds
ZA200509997B (en) Heteroaryl-Tetrahydropiperidyl compounds useful for treating or preventing pain
ZA200509562B (en) Piperdine compounds and pharmaceutical compositions containing them
ZA200604979B (en) Piperazines useful for treating pain
KR101733247B1 (en) Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
EP1487829B1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
US7071335B2 (en) 2-pyridinyl-1-piperazine therapeutic agents useful for treating pain
AU2006212761A1 (en) Combination therapy
CA2491079C (en) Therapeutic piperazine derivatives useful for treating pain
MXPA00012162A (en) Pharmaceutical combination that comprises a cox-2 inhibitor and an inhibitor of i
ZA200608886B (en) Indolyl derivatives as liver-X-receptor modulators
EP1648880A1 (en) Therapeutic agents useful for treating pain
WO2003059342A1 (en) Histamine-3 receptor ligands for diabetic conditions
ZA200505256B (en) Benzoazolypiperazine derivatives having mglur1-and mglur5-antagonistic activity
JP2015129150A (en) Role of n-2-hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
EP2210878B1 (en) Therapeutic agent for overactive bladder
US20030153548A1 (en) Histamine-3 receptor ligands for diabetic conditions
WO2010029995A1 (en) Therapeutic agent for pain
IL278077B1 (en) Method of treatment of non-alcoholic steatohepatitis, nash
JPS5970676A (en) Oxamide derivative and pharmaceutical composition containing the same
RU2007131105A (en) Pyrazole derivatives for the inhibition of cyclin-dependent kinases (CDK) and glycogen synthase kinases (GSK)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20191223

MKLA Lapsed

Effective date: 20191223